

CURRICULUM VITAE

Brent M. Egan, M.D.

Office Address:

Department of Medicine
Division of General Medicine
Medical University of South Carolina
135 Rutledge Avenue/11th Floor
Charleston, South Carolina 29425

Education:

1972–1974		University of Michigan
1974–1978	M.D.	University of Michigan

Postgraduate Training and Fellowship Appointments:

1978–1981		Resident, Internal Medicine University of Michigan
1981–1983		Hypertension Fellowship University of Michigan

Specialty Certification:

1981		American Board Internal Medicine
------	--	----------------------------------

Licensure:

1979–1988		Michigan (MI #41098)
1988–1992		Wisconsin (WI #29197)
1992 -		South Carolina (SC #16346)

Faculty Appointments:

1983–1985		Instructor, Internal Medicine University of Michigan
1985–1988		Assistant Professor, Internal Medicine University of Michigan
1988–1990		Assistant Professor, Internal Medicine Medical College of Wisconsin
1990–1992		Associate Professor, Internal Medicine

	Medical College of Wisconsin
1991–1992	Associate Professor, Physiology Medical College of Wisconsin
1992–1998	Assoc. Prof., Pharmacology & Med., Med. U. South Carolina (tenure 1/93)
1998-	Professor, Medicine & Pharmacology Medical University of South Carolina

Hospital Appointments:

1978–1988	U. of Michigan Medical Center Ann Arbor, Michigan
1988–1992	Milwaukee Co. Medical Complex Milwaukee, Wisconsin
1992–present	Medical Univ. of South Carolina Charleston, South Carolina

Administrative Appointments:

1988–1992	Director, Hypertension Unit Medical College of WI (MCW)
1990–1992	Associate Director, GCRC, MCW
1992–2002	Associate Director, GCRC Medical Univ South Carolina (MUSC)
2002-	Head, Hypertension Section, Division General Internal Medicine, MUSC

Other Appointments:

2006–2008	Executive Pastor, First Baptist Church Mt. Pleasant, SC
-----------	--

Awards, Honors:

1978	AOA, University of Michigan
1992	ASH, Young Scholars Award
1998 – 2008	U.S. News & World Report Best Doctors in America
1999–	ASH, Hypertension Specialist

2004	Dept of Health & Human Services Hypertension Initiative I – Best Practice Model II – Reducing Health Disparities
2005	Distinguished Researcher Award Int'l Society Hypertension in Blacks Distinguished Faculty Service Award Medical University of South Carolina

Memberships in Professional and Honorary Societies:

American Autonomic Society, 1994-1997
 American College of Angiology, Fellow, 1987-1990
 American Federation for Clinical Research, 1987-
 American Heart Association, Circulation, 1992-
 American Society for Clinical Pharmacology and Therapeutics, 1988- 1996
 American Society of Hypertension, 1988-
 ASH Hypertension Specialists, Examination Committee, 1999–2001
 Executive Council, 2000–2003
 Program Committee (2001–3 meetings)
 Vice-President, 2003–2006
 ASH Specialists Board, 2008 -
 ASH Carolinas-Georgia Chapter, founding member and President, 2001–2003
 Association of Black Cardiologists, 2000–2005
 Central Society for Clinical Research, 1988–1991
 Consortium of Southeast Hypertension Centers, 1994–2006
 Council for High Blood Pressure Research, Fellow, 1993-
 Vice-Chair, Program Committee AHA Annual Mtg., 2000
 Inter-American Society of Hypertension, 1992-
 International Society for the Study of Fatty Acids and Lipids, 1995-
 North American Association for the Study of Obesity, 1994-
 Southern Society for Clinical Investigation, 1994–2000
 International Society on Hypertension in Blacks, 1998-
 Executive Council, 2006-

Editorial Board Positions:

Hypertension Index and Reviews	1993 – 1998
Journal of Human Hypertension	1993 – 2006
Hypertension	1998 –
Ethnicity & Disease	1998 –
American Journal of Hypertension	2000 –
Journal of the American Nutraceutical Association	2002 –
Journal of Clinical Hypertension	2004 – 2007
Current Hypertension Reviews	2004 –
Therapeutic Advances in Cardiovascular Disease	2007 –

Research Grants, Contracts, Awards:

Previous:

NHLBI, 1K08 HL01353 Clinical Investigator Award, Alpha-adrenergic reactivity in human hypertension," 1984-1989, \$278,000. Principal Investigator (60% effort).

Pennwalt Pharmaceuticals: "Effects of guanadrel sulfate on α -adrenergic reactivity in mild hypertension," 1984, \$30,000, Co-Principal Investigator.

American Heart Association of Michigan, "Alpha-adrenergic reactivity in human hypertension," 1985-1986, \$17,500, Principal Investigator.

Janssen Pharmaceuticals: Mechanisms of ketanserin's antihypertensive action in elderly hypertensive men." 1986-87, \$59,800. Principal Investigator.

American Heart Association of Michigan, "Alpha-adrenergic reactivity in human hypertension," 1986-1988, \$40,000, Principal Investigator.

American Heart Association: Grant-in-Aid, "High vascular resistance, salt, and hypertension," 1987-1990, \$97,203. Principal Investigator.

American Heart Association, Wisconsin Affiliate, "The vascular endothelium in human hypertension," 1988-1989, \$14,434. Principal Investigator.

*Merck Sharp and Dohme, "Hypertension, hyperinsulinemia and coronary heart disease risk. A proposal to evaluate the potential utility of angiotensin converting enzyme inhibitors," 1989, \$15,000, PI.

Smith, Kline and French, Multicenter trial of carvedilol, atenolol and placebo in mild-moderate hypertension, 1990, \$44,353, Principal Investigator.

American Heart Association, Wisconsin Affiliate, "Overweight young men, insulin, and salt-sensitive hypertension," 1990-1992, \$65,000 TDC year 01, \$130,000 TDC project. PI (60% effort).

Merck Sharp & Dohme, "Effects of converting enzyme inhibition on insulin dynamics and insulin action in hypertensive men with upper body obesity," 1991-1992, \$217,500 project. PI.

ICI Pharmaceuticals, "Hemodynamic effects of lisinopril vs nifedipine in hypertensive patients over 55 years of age," 1991-1992, \$56,670. Principal Investigator.

ICI Pharmaceuticals, "A multicenter double-blind titration study comparing lisinopril (Zestril) with twice daily diltiazem HCL (180, 240 mg) in the treatment of hypertension in the elderly," 1991-2, \$87,408. PI.

ICI Pharmaceuticals, "Lisinopril and hydrochlorothiazide (HCTZ) in essential hypertension: "Effects on left ventricular structure and function," 1991-1992. \$30,000 project. PI. (PI changed to Dr. Sagar 8/1/92).

GCRC Program Grant (5M01-RR00058) 1991-1992. \$1,282,966 TDC year 01. Assoc. Prog. Dir. (20% effort).

Sandoz Pharmaceuticals, "A multicenter isradipine salt trial," 1992-1993, \$93,702 project. PI.

NIH-HLBI, R01 HL-43164, "Hyperinsulinemia and hypertension in overweight men," 1991-1996. \$579,578 TDC project. Principal Investigator (40% effort).

NIH-HLBI, R01 HL-43164 Administrative Supplement: Inclusion of women in research studies, 1991-1993. \$29,251 TDC supplement. Principal Investigator.

University Research Committee, "Oleic acid and vascular biology," 1996-7, \$25,727, TDC, Princ. Invest.

Stroke Belt Consortium, Videotape: "Worst to first in cardiovascular health," 1996, \$1,000, TDC, PI.

Astra-Merck: "Hypertension Optimal Treatment (HOT) Study," 1993-1997, \$13,599, TDC, PI.

Knoll Pharmaceutical Co., Study of sibutramine vs placebo in obese hypertensive patients controlled with a calcium channel blocker \pm diuretic, 1996-1997, \$184,266 TDC project, Co-PI with Dr. Patrick O'Neil, PI.

Innovex (Hoffman-LaRoche), Mibefradil vs verapamil SR in patients with hypertension, 1997, \$29,480, PI.

AHA, South Carolina, "Mechanism of the mitogenic response to oleic acid in vascular smooth muscle cells, 1996-1998. \$50,000, TDC, Principal Investigator.

University Research Committee, Shared equipment, \$20,000, 1998, PI.

Bristol-Myers Squibb, Assessment of medication use and comorbid conditions in hypertensive Medicaid recipients, 1997-9, \$25,000 TDC. Co-PI with Dr. Dan Lackland.

Eli Lilly, Open label safety study of sustained release moxonidine, 1998-9, \$58,431, PI.

Healthy South Carolina Initiative, Church-based approach to healthy lifestyle change, 1998-99, \$177,247, PI.

Roche Pharmaceuticals, Orlistat in obese hypertensive patients, 1999 – 2000, \$54,104 (total cost), PI.

NIDDK-PPG, Vascular disease and diabetes, Project 5: "Metabolic and genetic factors in IDDM vascular disease," \$3,520,607, 1996-2000. Co-Inv. Project 5 (10%). Principal Investigator: W. Timothy Garvey, MD.

NIH, Division of Research Resources, GCRC Program Grant, 1996-2000, \$6,246,367, Associate Program Director (15%). Program Director, Lyndon Key, M.D, PI, Layton McCurdy, M.D.

NIH U01 DK48650, Charleston study of kidney disease in African Americans, 1996-2001, \$1,209,354, TDC, Co-Investigator (5%). Principal Investigator, Deanna Cheek, M.D.

The Duke Endowment, A church-based approach to healthy lifestyle change, 2000–2002, \$375,000, TDC, PI, (transferred to Mary Joan Oexmann, Project Director).

Department of Health and Environmental Control, State of South Carolina, The Hypertension Initiative of South Carolina, \$125,000, 2000 – 2001, PI.

Astra-Zeneca, Hypertension Initiative of South Carolina, 2000 – 2001, \$125,000, PI.

NIH R01 HL58794, Effects of fatty acids on vascular reactivity, 1997- 3/31/2002, \$476,495, TDC, PI.

NIH R01 HL58794, Effects of fatty acids on vascular reactivity, Minority Research Supplement Award, 1998-2000, \$198,095, TDC.

2M01RR0170-25, General Clinical Research Center (GCRC), \$13,511,677, TDC, Associate Program Director (15%), L. Lyndon Key, Program Director, 2001–2006 (position relinquished 6/1/02 due to >100% federal funding).

K30 Award (Clinical investigator training grant), L. Lyndon Key, PI, 2001–2006 (Seminar Series Director, 8%, support relinquished 6/1/02 given commitments on other funded projects).

Merck, Inc., Medical School Grant, Angiotensin and oxidative stress in obese hypertensives, 2001-2002, \$65,000, PI.

Hypertension Initiative of South Carolina (State support), 2001–2002, \$100,000, Medical Director, PI.

Sanofi, Study of weight reducing effect of SR141716 in obese patients with type 2 diabetes (2nd project lipids), \$113,995 TC, 2002-3, PI.

Novartis Pharmaceutical Corporation, VALUE (Valsartan long-term use evaluation), 1998-2004, \$95,869, PI.

Astra-Zeneca, TROPHY (Trial of preventing hypertension) Study (main study, substudy site and chair), 1999 – 2004, \$300,000+ total costs (3 contracts), PI (1%).

Duke Foundation, “The Hypertension Initiative of South Carolina, 2002–2005, \$553,771, TC project, PI.

American Society of Hypertension, Hypertension Initiative data audit and feedback, \$95,000, TC, 2003–4, PI.

NIH-HLBI K24 HL04290, Minority supplement (Theodosha Gilliard), \$61,556, TC, 9/1/2003 – 8/31/2005.

CV Therapeutics, “Angina: Prevalence and management in primary care,” \$35,000, 2004, co-PI.

NIH-HLBI, R01 58794, Fatty acids, angiotensin and oxidative stress (investigates genetic polymorphisms contributing to salt sensitivity), Minority supplement (Eni Okonofua) to R01 HL58794-05, 9/1/02–3/31/05, \$315,661 (total costs).

NIH-HLBI R01 58794, Fatty acids, angiotensin and oxidative stress (investigates anti-hypertensive mechanism of the DASH intervention). \$1,065,000, TC, 4/1/02 – 3/31/07 (no-cost extension), PI (20%).

NIH-HLBI K24 HL04290 (midcareer clinical investigator award), Insulin resistance and cardiovascular risk factors, \$532,985, 2000–2007 (no-cost extension), PI (25%).

P01HS1087-01, Agency for Healthcare Research and Quality, “Understanding and eliminating health disparities in blacks,” \$8,844,516, TDC PPG. Project 1: Reducing the racial disparity in CV disease through better BP control, Project Leader (B. Egan [20%]). Principal Investigator, Barbara Tilley, Ph.D., 2000–2006 (including no-cost extension).

Novartis-CSPP100A2306 “Aliskirin-A 26 week, double-blind, randomized, multicenter, parallel group, active-controlled study comparing aliskiren to ramipril with optional addition of hydrochlorothiazide, followed by a 4 week double-blind, randomized placebo-controlled withdrawal in patients with essential hypertension.” \$73,600 total costs, 2/05-06/06, PI.

Pfizer, Inc., “Dihydropyridine calcium channel blockers blood pressure control in diabetic hypertensive patients,” \$137,500, 2004–2006, PI.

NIH-HLBI, R01 HL076771-01 Dietary Fiber and Cardiovascular Inflammatory Markers, \$926,556, 2004-2007 . Principle Investigator, Dana King, MD, PI (Co-Investigator, 10%).

NHLBI-P60-MD00267-01 EXPORT Center on metabolic syndrome and minority health, 10/1/02–9/30/07, \$3,747,470 total costs, Center Co-Director [10%] (Sabra Slaughter, PhD, PI, Center Director).

Cornell/New York Presbyterian Hospital, “Renin-guided treatment of hypertension,” \$150,000, TC, 2004–8, PI.

Cooperative Agreement, Department of Health & Human Services. “Stroke Belt Initiative to Reduce the Burden of Stroke,” \$2,500,000, total costs, 9/1/04–8/31/08, PI (20%).

Novartis-CCIB002I2301 “ACCOMPLISH-Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension.” \$251,168, 5/1/04-6/1/08, PI.

AstraZeneca-PATH (PARTnership to Treat Hypertension) Study, \$388,543 total costs, 2006–8, PI, 10%.

Current:

State of South Carolina, Hypertension Initiative, PI, \$1,024,000 TDC. 7/1/07–6/30/09.

NIH-R01 07080684, Mechanisms of hypertension, PI (site), \$19,016, 7/1/2005-6/30/2009, 2%. Crystal Gadegbeku-PI (Michigan).

Abt. Daiichi/Sankyo. Cardiovascular risk factor control and healthcare utilization in hypertensive Medicaid recipients, PI, \$73,549, 3/1/08–2/28/09.

RTI, Therapeutic inertia in hypertensive Medicaid recipients, PI, \$9,976, TC. 10/07–9/08.

NIH R01 DK067615, Improving safety and access for physical activity, 4/1/07-3/31/2011, \$65,762, PI (Site) Dawn Wilson-PI (USC).

South Carolina Medical Association, “Diabetes Connect” (Initiative providing practice data management in a 3-way collaboration including SC DHEC), \$45,000, Jan–Dec 2009 (PI, MUSC).

NIH/NIDDK, R01DK067615, Improving safety and access for physical activity. PI (Site) SAMMPRIS 4/2007-3/2011.

NHLBI HL091841, “Collaborative Model to Improve BP Control and Minimize Racial Disparities. 03/09/09 – 04/30/12. Total costs \$8,482,800. Consultant (PI, Barry Carter, Iowa).

Academic and other committee activities:

1990–1992	Clinical Research Center Advisory Committee, Medical College of WI
1990–1992	Institutional Research Cmte., MCW
1991–1992	Strategic Research Planning, MCW
1991–1992	Cardiovascular Research Institute Planning Committee, MCW
1994–2003	Consortium Southeast Hypertension Centers (COSEHC), Exec. Cmte.
1993–	Graduate Studies Faculty, MUSC
1993–1995	University Research Cmte., MUSC
1993–2003	GCRC, Review Committee, MUSC
1993–1996	AHA Program Committee, Council for High Blood Pressure Research
1994–1997	Council for High BP Research, Education Committee
1995	Program Chair, 2nd COSEHC Mtg.
1995–2001	Commun-I-Care, Advisory Board Executive Committee, 1996- Prog Evaluation Cmte, Chair, 1996-
1997-	Reader Adv. Board, Mayo Clinic Proc.

1997–2002	Data and Safety Monitoring Board, Genetics of response to antihyperten
1997	AHA, SC, Advisor, Subcommittee on Heart & Stroke legislation
1998 -	Steering Program Committee, Medical Scientist Training Program, MUSC
1998 -	Value Trial, U.S. Policy Committee
1998–2006	TROPHY Trial, Executive Committee, Co-Chair, Chair, Substudy Committee
1999–2000	Medical Liaison, Dietetic Internship Program, MUSC AHA, Working Group, Nutrition, Metabolism & Phys. Act. Council
1999 -	ASH, Hypertension Specialist Program Exam Development Cmte.
2001–	Advisory Member, Diabetes Initiative of South Carolina
2000–2003	ASH, Executive Committee
2003–2006	ASH, Vice-President
2004–2005	Heart.org, Hypertens Steering Cmte
2005–2007	ASH, Chapter Relations Cmte, Chair
2006–	ISHIB, Executive Council Co-Chair, Obes & Metab Synd Cmte

Invited Lectures, scientific session chair:

1988	<ul style="list-style-type: none"> • University of Tennessee, Memphis. Regional vascular reactivity. • Med College of Virginia, Richmond. Cardiopulmonary baroreceptors.
1989	<ul style="list-style-type: none"> • Cornell University, New York, NY. Neurogenic hypertension.
1990	<ul style="list-style-type: none"> • Mayo Clinic, Rochester, MN. Vascular alpha-adrenergic reactivity. • Symposium on regional body fat pattern. Osaka, Japan. Obesity Htn.
1991	<ul style="list-style-type: none"> • University of Chicago, Chicago, IL. Obesity and vascular reactivity. • University of Texas, Galveston, TX. Insulin resistance and Htn. • University of Michigan, Ann Arbor. Obesity & insulin resistance. • Indiana University, Indianapolis, IN. Regional vascular reactivity.
1992	<ul style="list-style-type: none"> • University of Wisconsin, Madison, WI. Obesity & salt sensitivity.

- Neurogenic Htn Conf., Santa Margherita, Italy. Obesity hypertension.
- 1993
- University of Wisconsin, Madison, WI. Insulin resistance & htn.
 - University of Alabama (Destin, FL) Vascular Biology and Research.
 - North American Association for the Study of Obesity, Milwaukee, WI
 - AHA Cardiovasc Conf, Council for High BP Research, Atlanta, GA
- 1994
- Wake Forest Univ., Bowman-Gray, Winston-Salem, NC
 - Council for High BP Research, Co-Chair, Obesity/Insulin resistance
 - Sodium and Health Conference, Internat. Life Sciences, Arlington, VA
 - Maharishi International Univ., Fairfield, Iowa. Neurogenic htn.
- 1995
- Wayne State Univ., Detroit, Michigan. Obesity hypertension.
 - Med. College Georgia, Augusta, GA. Obesity & insulin resistance.
 - Inter-American Soc. of Htn. Vasculature in diabetes, Montreal.
 - Hyperten Optimal Treatment Symposium. ASH. New York, NY.
 - U. of Mississippi, Jackson, MS. Insulin resistance & vasc reactivity.
- 1996
- University of Minnesota, Minneapolis. Obesity and hypertension.
 - Am Soc Htn, Co-Chair, Pre-adult influences on BP, New York
 - COSEHC, Raleigh-Durham, NC.
- 1997
- Angiotensin & CV disease, European Heart House, Nice, France
 - Fatty acids & vascular biology. USC, Los Angeles, CA
 - Obesity htn, S Med Assoc, Hypertension Conf., Palm Beach, FL
 - Obesity, insulin resistance & high BP. 4th COSEHC Mtg., Orlando, FL
 - Fatty acids, ang II & vascular biology, Copenhagen, Denmark
 - Fatty acids, vascular reactivity & growth, U. Western Ontario, Canada
- 1998
- U. of Alabama, Dept. of Psychiatry, Behav. Med., Birmingham, AL
 - S.C. State U., mini-med school lecture on htn, Orangeburg, SC
 - Benedict College, mini-med school lecture on htn, Columbia, SC
 - 4th Int'l Roundtable on fatty acids and cell signaling, Chatham, MA
 - Council for HBP Research, Co-Chair, Insulin resistance and obesity
 - Fatty acids, angiotensin, & vascular pathology, U of MI, Ann Arbor
- 1999
- Sodium BP Workshop, NHLBI, Bethesda. Adverse effects of low salt.
 - VA Hypertension Strategic Planning, Washington, DC
 - Southern Medical Assoc, 3rd Annual Htn Conf, Kiawah Island, SC
 - 6th Annual COSEHC Mtg., San Juan, Puerto Rico (Na & BP, JNC VI)
- 2000
- Association of Black Cardiologists 5th Cardio. Summit, Savannah, GA
 - Fuller Conference, London, Ontario, Insulin and the vasculature.
 - Rush-Presb.-St. Luke's, Chicago, IL. New perspective on the cluster.
 - SC Med Assoc Annual Mtg., Charleston. Hyperten: Worst to first.
 - Georgetown University, Washington, DC. The metabolic syndrome.
 - Int'l Soc. of Hypertension, Breakfast symp (chair): Obesity & Htn.
 - Ann Arbor Hypertension 2000: Fatty acids and hypertension.
 - U of Mississippi, Jackson, MS. Grand Rounds: NEFAs & CVD.
 - U of Mississippi, Jackson, MS. Physiology Conf: NEFAs & BP.
 - University of Alabama, Birmingham, Center for Aging: Lighten Up.
 - SMA. Hypertension Update: Diagnosis and evaluation, Orlando.
 - 7th COSEHC Mtg., Savannah, GA; Obesity & Htn, session chair.

- 2001
- American Health Quality Assoc, Technical Conf., Los Angeles, CA
 - TROPHY Investigators meeting, Orlando, FL (speaker; session chair)
 - ASH Meeting, Beyond JNC VI (satellite symposium), San Francisco
 - ASH Meeting, Co-Chair: Insulin resistance syndrome. San Francisco
 - Emory University, Renal Conference, Fatty acids and CV risk.
 - MUSC, Dean's Seminar. Preventing CVD community partnerships.
 - Mt. Sinai Hospital, NY, NY. Building community partnerships.
 - COSEHC, Co-Chair & speaker: ASH Chapter; COSEHC genetics.
 - DR. CHIP (Danville, VA). Lifestyle approaches to CV risk reduction.
 - Canadian Hypertension Soc., Halifax. Diabetes & Htn; role of NEFAs.
 - Int'l Soc. Obesity & Htn, Berlin. NEFAs and vascular biology.
- 2002
- CVRI, Morehouse School of Medicine. Fatty acids CV disease.
 - Nat'l CV Health Conf., Integrative Medicine Approaches, Washington.
 - Nat'l CV Health Conf., Community approaches to CV Health.
 - Duke Clinical Research & FDA, The metabolic syndrome, Washington
 - ISHIB. Miami, FL. Intensive management of the risk factor cluster
 - ISHIB. Miami, FL. Ethnic minorities in research: Special issues.
 - Htn Center, Wake Forest U. Obesity: Oxidative stress.
 - 25th Japanese Htn Society: Tokyo. Systolic hypertension
 - 4th Sendai Htn Symposium: Insulin resistance and obesity htn
 - 9th COSEHC Conf., Savannah, GA. Vascular effects of BP meds
 - 9th COSEHC Conf., Session Chair: Lifestyle change
 - Penn State, Noll Laboratory. The metabolic syndrome and fatty acids
- 2003
- ASH 18th Annual Meeting, NYC. The dysmetabolic syndrome
 - ASH 18th Annual Meeting, NYC. Discussant: The Laragh BP method
 - U of WI, Madison, Endocrine Grand Rounds. Metabolic Syndrome.
 - COSEHC, 10th COSEHC Mtg, Coral Gables, FL. Chair, Metabolic Syn
 - Htn Center, 10th Anniversary, Wake Forest U., Metabolic Syndrome
- 2004
- SMA, 8th Summer Hypertension Conference, Hilton Head, SC
 - ISHIB Annual Mtg., 'Reducing disparities in BP control, Detroit, MI
 - SMA Annual Mtg., New Orleans, LA, 4 lectures on CV risk & disease
 - University of Rochester, Cardiology Grand Rounds, Htn Initiative
 - FDA/DCRI, Combination Pills in CVD, CV Risk in 1^o care, Wash, DC
- 2005
- Cardiovascular Best Topics 2005, TROPHY Study, Barcelona Spain
 - FDA/CDC, Polypill in CVD, Atlanta, GA
 - ASH 20th Annual Meeting, San Francisco, CA (4 sessions)
 - SMA, 9th Summer Hypertension Conference, New Orleans, LA
 - Cardiovascular Grand Rounds, U. of Wisconsin, Madison, WI
 - AHA, Hypertension Summer School, Castine, ME
 - COSEHC 12th Annual Mtg., Nashville, TN
 - Mayo Clinic, Nephrology-Hypertension Grand Rounds
 - University of Toronto, Nephrology City-Wide Grand Rounds
 - South Carolina Research Nutrition Consortium, Columbia, SC
 - Institute for Multicultural Health, Henry Ford Hospital, Detroit, MI
- 2006
- Cardiovascular Best Topics 2005, TROPHY Study, Barcelona, Spain
 - Morehouse School of Medicine, regional workshop and national symposium, "Healthcare challenges and opportunities post-Katrina"
 - Emory Univ., Cardiology Grand Rounds, "Hypertension Initiative"

- ASH Annual Mtg, (1) Current Controversies in Treating Hypertension, (2) How to develop a community hypertension program (3) Trial of Preventing Hypertension. NY, NY
 - SMA Summer Hypertension Meeting (4 lectures), Myrtle Beach, SC
- 2007
- ASH Annual Mtg., (1) Satellite Symposium. Novel insights into cardiometabolic disease. Session Chair (2) Biochemical predictors of Antihypertensive drug responses, lecture. Chicago, IL
 - IASH/COSEHC. Renin-angiotensin system and the cardiometabolic syndrome, lecture. Miami, FL.
 - The Society of Nephrology and Hypertension of Puerto Rico, Annual Mtg., (1) The RAS in metabolic syndrome (2) Metabolic syndrome and the kidney. Fajardo, Puerto Rico.
- 2008
- Spanish Hypertension Society Mtg., Prehypertension, Valencia, Spain
 - SMA, Summer Hypertension Mtg., Lecturer, Panel Discussant
 - SC Primary Health Care Assoc., Hypertens Initiative, Myrtle Beach, SC
- 2009
- DHEC/SCPHCA., 7th Annual Diabetes, Heart Disease & Stroke Winter Symposium, Myrtle Beach, SC
 - MUSC Stroke Center, Integrated Stroke and Cerebrovascular Conference, Stroke Prevention in Primary Care, Wild Dunes, SC

Trainees:

a. <u>Faculty</u>	<u>Year</u>	<u>Institution</u>	<u>Project</u>
i. *Crystal Gadegbeku, M.D. (minority suppl and K23)	1998-2003	MUSC/U MI	NEFAs, vasoreact., renal dz
ii. Sunil Patel, M.D., Ph.D. (K23)	1998-2006	MUSC	Central BP regulation
iii. Nancy Diehl, Ph.D. (AHA)	1999-2001	MUSC	Exercise in African American.
iv. *Eni Okonofua, M.D. (min suppl)	2002-2006	MUSC	Antioxidants and BP.
v. Dana King M.D.	2002-2004	MUSC	CRP, fiber & exercise
vi. Shak Rehman, M.D.	2003-2005	MUSC	BP & health disparities
vii. *Michael Armstrong, M.D.	2003-2005	MUSC	Oxidative stress, pre-eclampsia
viii. Neal Axon, MD	2007 -	MUSC	Hypertension care transition
b. <u>Post-doctoral fellows</u>			
i. Alan Hinderliter, M.D.	1984-1985	U. of Michigan	Regional vasoreactivity
ii. Roberto Panis, M.D.	1984-1986	U. of Michigan	Regional vasoreactivity
iii. Agnes Mejia, M.D.	1986-1988	U. of Michigan	Resistant hypertension
iv. Jurij Petrin, M.D.	1987-1988	U. of Michigan	Regional vasoreactivity
v. Abed Sekkarie, M.D.	1987-1988	U. of Michigan	α -receptor sensitivity
vi. Dermot Kenny, M.D.	1990-1991	Med Coll of Wisc	Fish oil, vasoreactivity
vii. Michael Fleissner, M.D.	1991-1992	Med Coll of Wisc	Hypertension in elderly
viii. J. Michael Neahring, M.D.	1991-1992	Med Coll of Wisc	Insulin & vasoreactivity
ix. Hyun H. Shin, M.D.	1991-1992	Med Coll of Wisc	Signal-averaged ECGs
x. Pietro Nazzaro, M.D.	1991-1993	MCW/MUSC	Insulin resistance & Htn
xi. K. Stepniakowski, MD, PhD	1991-1996	MCW/MUSC	Insulin resistance & Htn
xii. Gang Lu, M.D.	1994-1999	MUSC	NEFAs, cell growth
xiii. *Adetola Haastrup, M.D.	1997-1999	MUSC	NEFAs & vasoreactivity
xiv. Da Zhang, M.D., Ph.D.	1999-2000	MUSC	NEFAs, oxidative stress
xv. Milos Stojiljkovic, M.D., Ph.D.	1999-2000	MUSC	NEFAs, angiotensin, & ROS
xvi. Heno Lopes, M.D., Ph.D.	2000-2001	MUSC	NEFAs & neuro BP control
xvii. Khaled Nashar, M.D.	2001-2002	MUSC	NEFAs, Ang II, isoprostanes

xviii.	Amar Jessri, M.D.	2002-2005	MUSC	Antioxidants and BP control
xix.	Phillip Strange, M.D.	2004-2005	MUSC	Renin and BP regulation
xx.	Karinka Romanowska, M.D.	2004-2005	MUSC	DASH diabetic hypertensive
xxi.	Curtis Grob, M.D.	2005-2006	MUSC	DASH, Hypertension Initiative
xxii.	Yaser Al-Solaiman, M.D.	2005-2006	MUSC	DASH
xxiii.	Keidre Corbett-Jenkins, MD	2006-2007	MUSC	Predictors of renal disease
c. <u>Graduate students</u>				
i.	Jessica Riehle	2003-4	MUSC	Hypertension Initiative
ii.	*Theodosha Gilliard (minority supplement)	2003-5	MUSC	Project EXPORT
d. <u>Undergraduate students</u>				
i.	*Valerie Holloway (Pharmacy)	1995	MUSC	NEFAs & vasoreactivity
ii.	*Nina Sheats	2003, 2004	MUSC	BP & ethnic disparities
iii.	*Taneika Young	2003	MUSC	DASH intervention
iv.	*Jennifer Forsythe	2004	MUSC	Genetics of salt sensitivity
e. <u>Medical students</u>				
i.	Grigory Sorokin	1991	MCW	Ang II & chorionic art.
ii.	*Christine Lee	2000	MUSC	Na ⁺ balance and ROS
iii.	*Sheryl Montgomery	2002	MUSC	Antioxidants and BP
iv.	*Robyn Brewer	2004	MUSC	DASH & obesity hypertension
f. Pharmacy students				
i.	Meredith Knox	2004-2005	MUSC	Hypertension Initiative
ii.	*Hong Nguyen	2004-2006	MUSC	Hypertension Initiative
g. High school student				
i.	*Joey Malamug	1997	MUSC	NEFAs & cell growth

* Minority trainee/investigator

Extramural review committees:

1992	NIH, Behavioral Medicine, Ad hoc reviewer
1992, 1994	Department of Veterans Affairs Ad hoc reviewer, Merit Reviews
1993–1997	NIH, Behavioral Medicine
1993, 1995	Housing and Urban Development, Human Develop. and Aging, Behavioral and Neurosci, Ad hoc
1993-1995	AHA, National Grant-in-Aid Review Committee Member
2003	NHLBI, Winter Hypertension P01 Special Review Group
2009	CDC U48 (Prevention Center) Special Review Group

Site Visits:

1. NASA Specialized Centers of Research (SCOR) and Training
 - a. University of Texas Southwestern
Medical Center at Dallas Texas, January 18-20, 1993
 - b. Vanderbilt University, Nashville, TN
January 27-29, 1993
2. GCRC, University of Southern California, Los Angeles, CA
April 15-16, 1993
3. U. of Michigan, annual extramural review for PPG, Dept. of Physiology [PI, R. Clinton Webb, Ph.D.],
Chair, extramural review/advisory group, September 11, 1996.
4. Morehouse School of Medicine, NASA Program Project Grant, external advisory committee review,
November 13, 1997.

BIBLIOGRAPHY

Journals:

1. Ibsen H, Egan B, Osterziel K, Julius S: Reflex hemodynamic adjustments and baroreflex sensitivity during converting enzyme inhibition with MK-421 in normal man. *Hypertension* 1983;5 (Suppl I):I-184-I-191.
2. Julius S, Cottier C, Egan B, Ibsen H, Kiowski W: Cardiopulmonary mechanoreceptors and renin release in humans. *Federation Proc* 1983;42:2703-2708.
3. Egan B, Julius S, Cottier C, Osterziel KJ, Ibsen H: The role of cardiovascular receptors on the neural regulation of renin release in normal man. *Hypertension* 1983;5:779-786.
4. Ibsen H, Egan B, Julius S: Baroreflex sensitivity during converting enzyme inhibition with enalapril (MK-421) in normal man. *J Hypertension* 1983;1 (Suppl 2):222-224.
5. Egan B, Grekin R, Ibsen H, Osterziel K, Julius S: The role of cardiopulmonary mechanoreceptors in the ADH release in normal man. *Hypertension* 1984;6:832-836.
6. Egan B, Neubig R, Schneider R, Julius S: Methods for measuring vascular and nonvascular alpha-receptor sensitivity in humans. *J Cardiovasc Pharm* 1985;(Suppl 6):S153-S158.
7. Egan B, Julius S: Vascular hypertrophy in borderline hypertension: Relationship to blood pressure and sympathetic drive. *Clin Exp Hypertension* 1985;A7:243-255.
8. Egan B, Neubig R, Julius S: Pharmacologic reduction of sympathetic drive increases platelet alpha₂-receptor number. *Clin Pharm Therap* 1985;38:519-524.
9. Schneider RH, Egan BM, Johnson EH, Drobny H, Julius S: Anger and anxiety in borderline hypertension. *Psychosom Med* 1986;48:242-248.
10. Fitzpatrick MA, Hinderliter AL, Egan BM, Julius S: Decreased venous distensibility and reduced renin responsiveness in hypertension. *Hypertension* 1986;8 (Suppl II):II-36-II-43.
11. Egan B: Management of the patient with borderline hypertension. *J Card Pharm* 1986;8 (Suppl 5):S103-7.
12. Egan B, Fitzpatrick MA, Julius S: The heart and the regulation of renin. *Circ* 1987;75 (Suppl I):I-130-3.
13. Weder AB, Fitzpatrick MA, Torretti BA, Hinderliter AL, Egan BM, Julius S: Red blood cell Li⁺-Na⁺ counter-transport, Na⁺-K⁺ cotransport, and the hemodynamics of hypertension. *Hypertension* 1987;9:459-66.
14. Egan B, Panis R, Hinderliter A, Schork N, Julius S: Mechanism of increased α-adrenergic vasoconstriction in human essential hypertension. *J Clin Invest* 1987;80:812-817.
15. Egan BM, Schork N, Panis R, Hinderliter A: Vascular structure enhances regional resistance responses in mild hypertension. *J Hypertension* 1988;6(1):41-48.
16. Egan BM, Conlon M, Campbell R, Schork N, Zweifler A, Julius S: Effects of ketanserin on blood pressure and platelet aggregation in elderly men. *Am J Hypert* 1988;1:324S-330S.

17. Shenker Y, Bates E, Egan B, Hammoud J, Grekin R: Effects of vasopressors on plasma levels of immunoreactive atrial natriuretic hormone in normal man. *Hypertension* 1988;12:20–25.
18. Egan BM, Schouder R: The importance of hemodynamic considerations in essential hypertension. *Am Heart J* 1988;116:594–599.
19. Weder AB, Egan BM: Erythrocyte water, Na⁺-K⁺ cotransport and vascular function in humans. *Hypertension* 1988;12:199-205.
20. Egan BM, Schork NJ, Weder AB: Regional hemodynamic abnormalities in overweight men. Focus on alpha-adrenergic vascular responses. *Am J Hypertension* 1989;2:428-434.
21. Egan B, Fitzpatrick MA, Juni J, Buda A, Zweifler A: Importance of overweight in studies of left ventricular hypertrophy and diastolic function in mild systemic hypertension. *Am J Cardiol* 1989;64:752-755.
22. Dananberg J, Egan BM, Bates ER, Grekin RJ: Sustained saline-induced secretion of atrial natriuretic factor is not maintained by atrial stretch. *J Clin Endocr Metab* 1989;68:735-739.
23. Petrin J, Egan B, Julius S: Increased beta-adrenergic tone enhances arterial compliance in hyperkinetic borderline hypertension. *J Hypertension* 1989;7(suppl 6):S78-S79.
24. Egan BM: Neurogenic mechanisms initiating human essential hypertension. *Am J Hyper* 1989;2:357S-62.
25. Mejia A, Egan B, Schork N, Zweifler A: Importance of blood pressure measurement artefacts and lack of target organ involvement in the assessment of patients with treatment resistant hypertension. *Ann Int Med* 1990;112:270-277.
26. Sekkarie A, Egan B, Neubig RR, Supiano MA: Sensitization of alpha₁ and alpha₂ adrenergic venous responses by guanadrel sulfate. *J Clin Pharmacol Ther* 1990;48:537-543.
27. Egan BM, Bassett DR, Block WD: Comparative effects of overweight on cardiovascular risk in younger vs older men. *Am J Cardiology* 1991;67:248-252.
28. Egan BM, Weder AB, Petrin J, Hoffmann RG: Neurohumoral and metabolic effects of short-term NaCl restriction in man: Relationship to salt sensitivity status. *Am J Hypertension* 1991;4:416-421.
29. Goodfriend TL, Ball DL, Weinberger MH, Moore TJ, Weder AB, Egan B: Salt loads raise plasma fatty acids and lower insulin. *Hypertension* 1991;17:958-964.
30. Egan BM, Petrin J, Hoffmann RG: NaCl induces differential changes of regional vascular reactivity in salt-sensitive versus salt-resistant men. *Am J Hypertens* 1991;4:924-931.
31. Egan BM: Neurohumoral, hemodynamic and microvascular changes as mechanisms of insulin resistance: A provocative but partial picture. *Int J Obesity* 1991;15:133-139.
32. Weder AB, Egan BM: Potential deleterious impact of dietary salt restriction on cardiovascular risk factors. *Klin Wochensh* 1991;69 (Suppl XXV):45-50.
33. Sorokin G, Egan BM, Lombard JH: Cyclooxygenase products do not modulate angiotensin II induced contractions of human chorionic plate arteries. *Am J Obst Gyn* 1992;167:110-114.
34. Kenny D, Warltier DC, Pleuss J, Hoffmann RG, Goodfriend TL, Egan BM: Omega-3 fatty acids selectively reduce vascular response to angiotensin. *Am J Cardiol* 1992;70:1347-1352.
35. Shin HH, Sagar KB, Stepniakowski K, Wetherbee JN, Egan BM: Increased prevalence of abnormal signal-averaged electrocardiograms in elderly hypertensive patients with low diastolic blood pressure. *Am Heart J* 1993;125:1698-1703.
36. Egan BM, Stepniakowski K: Effects of enalapril on the hyperinsulinemic response to severe salt restriction in obese young men with mild hypertension. *Am J Cardiol* 1993;72:53-57.
37. Neahring JM, Stepniakowski K, Greene AS, Egan BM: Insulin does not reduce forearm α -vasoreactivity in obese hypertensive or lean normotensive men. *Hypertension* 1993;22:584-590.
38. Egan B, Fleissner MJ, Stepniakowski K, Neahring JM, Sagar K, Ebert T. Improved baroreflex sensitivity in elderly hypertensives on lisinopril is not explained by BP reduction alone. *J Hypertens* 1993;11:1113-20.
39. Egan BM, Stepniakowski K, Zweifler AJ: Ketanserin's sympatholytic and serotonin₂-receptor blocking actions precede the hypotensive effects. *J Hum Hypertens* 1994;8:59-64.
40. Egan BM, Stepniakowski K, Nazzaro P: Insulin levels are similar in obese salt-sensitive and salt-resistant hypertensives. *Hypertension* 1994;23 [Suppl I]:I1-I7.
41. Nazzaro P, Stepniakowski K, O'Shaughnessy IO, Kissebah AH, Egan BM: Elevated BP in obese young men with mild hypertension are sustained during the day and night. *Am J Hypertension* 1994;7:609-614.

42. Egan BM, Stepniakowski K: Compensatory hyperinsulinemia and the forearm vasodilator response to an oral glucose tolerance test in obese hypertensives. *J Hypertension* 1994;12:1061-1067.
43. Egan BM, Stepniakowski K, Goodfriend TL: Renin and aldosterone are higher and the hyperinsulinemic effects of salt restriction greater in subjects with risk factor clustering. *Am J Hypertens* 1994;7:886-893.
44. Kenny D, Egan B: Is there a role for fish oil in hypertension? *J Hum Hyper* 1994;8:896-905.
45. Goodfriend TL, Egan BM, Stepniakowski K, Ball D: Relationships among plasma aldosterone, HDL cholesterol and insulin in humans. *Hypertension* 1995;25:30-36.
46. Stepniakowski KT, Egan BM: Additive effects of hypertension and obesity to limit venous distensibility. *Am J Physiol* 1995;268:R562-R568.
47. Stepniakowski KT, Goodfriend TL, Egan BM: Fatty acids enhance vascular α -adrenergic sensitivity. *Hypertension* 1995;25[part2]:774-778.
48. Kjeldsen SE, Weder AB, Egan B, Neubig R, Zweifler AJ, Julius S: Effect of circulating epinephrine on platelet function and hematocrit. *Hypertension* 1995;25:1096-1105.
49. O'Shaughnessy IM, Myers TM, Stepniakowski K, Nazzaro P, Kelly TM, Hoffman RG, Egan BM, Kissebah AH: Glucose metabolism in obese hypertensives and normotensives. *Hypertension* 1995;26:186-192.
50. Davda RK, Stepniakowski KT, Lu G, Ullian ME, Goodfriend TL, Egan BM: Oleic acid inhibits endothelial cell nitric oxide synthase by a PKC-independent mechanism. *Hypertension* 1995;26:764-770.
51. Egan BM, Hennes MMI, O'Shaughnessy IM, Stepniakowski KT, Kissebah AH, Goodfriend TL: Obesity hypertension is more closely related to impairment of insulin's fatty acid than glucose lowering action. *Hypertension* 1996;27[part 2]:723-728.
52. Ullian ME, Hazen-Martin DJ, Walsh LG, Davda RK, Egan BM: Carbenoxolone damages endothelium and enhances vasoconstrictor action in aortic rings. *Hypertension* 1996;27:1346-1352.
53. Hennes MM, O'Shaughnessy IM, Kelly TM, Labelle P, Egan BM, Kissebah AH: Insulin resistant lipolysis in abdominally-obese hypertensives: Role of the renin-angiotensin system. *Hypertension* 1996;28:120-126.
54. Stepniakowski KT, Sallee FR, Goodfriend TL, Zhang Z, Egan BM: Fatty acids enhance neurovascular reflex responses by effects on α_1 -adrenoceptors. *Am J Physiol* 1996;270:R1340-R1346.
55. Alexander CN, Schneider RS, Claybourne M, Sheppard W, Staggers F, Rainforth M, Salerno J, Kondwani K, Smith S, Walton KG, Egan B: A trial of stress reduction for hypertension in older African Americans (Part II): Gender and risk subgroup analysis. *Hypertension* 1996;28:228-237.
56. Lu G, Morinelli TA, Meier KA, Rosenzweig SA, Egan BM: Oleic acid-induced mitogenic signaling in vascular smooth muscle cells: A role for protein kinase C. *Circ Res* 1996;79:611-618.
57. McCarron DA, Weder AB, Egan BM, Krishna GG, Cohen M, Oparil S: Blood pressure and metabolic responses to moderate sodium restriction in isradipine-treated hypertensive patients. *Am J Hypertension* 1997;10:68-76.
58. Stepniakowski KT, Lu G, Miller GD, Egan BM: Fatty acids, not insulin, modulate α_1 -adrenergic reactivity in dorsal hand veins. *Hypertension* 1997;30:1150-1155.
59. Stepniakowski KT, Lu G, Davda RK, Egan BM: Fatty acids enhance endothelium-dependent dilation in hand veins by a cyclo-oxygenase dependent mechanism. *Hypertension* 1997;30:1634-1639.
60. Lu G, Meier KE, Jaffa AA, Rosenzweig SA, Egan BM: Oleic acid and angiotensin induce a synergistic mitogenic response. *Hypertension* 1998;31:978-985.
61. Barone BM, Egan BM, Brown TE, Resch ML, Woodard LJ, Trogdon KP, Jr., Lackland DT: Commun-I-Care: Experience in the first four years. *J South Carolina Med Assoc*; pgs 311-315, July, 1998.
62. Haastrup T, Stepniakowski KT, Goodfriend TL, Egan BM: Lipids enhance α_1 -adrenergic receptor mediated pressor reactivity. *Hypertension* 1998;32:693-698.
63. Lu G, Greene EL, Nagai T, Egan BM: Reactive oxygen species are critical in the oleic acid-mediated mitogenic signaling pathway in vascular smooth muscle cells. *Hypertension* 1998;32:1003-1010.
64. Lackland DT, Egan BM, Jones PJ: Impact of nativity and race on stroke belt mortality. *Hypertension* 1999;34:57-62.
65. Oexmann MJ, Thomas JC, Taylor KP, O'Neil PM, Garvey WT, Lackland DT, Egan BM: Short-term impact of a church-based approach to lifestyle change on cardiovascular risk in African Americans. *Ethnic Dis* 2000;10:17-23.

66. Lackland DT, Bendall HE, Oxmond C, Egan BM, Barker DJP: Low birthweight contributes to the high rates of early onset chronic renal failure in the Southeast United States. *Arch Int Med* 2000;160:1472-1476.
67. Gajjar D, Egan B, Cure J, Rust P, Van Tassel P, Patel SJ: Vascular compression of the ventro-lateral medulla in sympathetic-mediated essential hypertension. *Hypertension* 2000;36:78-82.
68. Greene EL, Lu G, Zhang D, Egan BM: Signaling events mediating the additive effects of oleic acid and angiotensin II on vascular smooth muscle cell migration. *Hypertension* 2001;37:308-312.
69. Stojiljkovic MP, Zhang D, Lopes HF, Lee CG, Goodfriend TL, Egan BM: Hemodynamic effects of lipids in humans. *Am J Physiol* 2001;R280:1674-1679.
70. Egan BM, Lackland DT, Williams B, Gunter N, Tocharoen A, Beardon L: Health improvement and cost-avoidance opportunities in hypertensive Medicaid beneficiaries. *J Clin Hypertension* 2001;3:279-282.
71. Lopes HF, Stojiljkovic MP, Zhang D, Goodfriend TL, Egan BM: The pressor response to acute hyperlipidemia is enhanced in lean normotensive offspring of hypertensive parents. *Am J Hypertension* 2001;14:1032-1037.
72. Oexmann MJ, Ascanio R, Egan BM: Preventing cardiovascular disease: Efficacy of a church-based intervention on cardiovascular risk reduction. *Ethnic Dis* 2001;11:817-822.
73. Haastrup A, Gadegbeku CA, Zhang D, Mukhin UV, Greene EL, Jaffa A, Egan BM: Intralipid stimulates the production of 6-keto-PGF_{1α} in human dorsal hand veins. *Hypertension* 2001;38:858-861.
74. Diehl NS, Lewis-Stevenson S, Spruill I, Egan BM: Cardiovascular disease risk, physical activity, and self-efficacy in National Black Nurses Association conference attendees. *J Nat'l Black Nurses Assoc* 2001;12:10-15.
75. Lackland DT, Egan BM, Syddall HE, Barker DJP: Birth weight influences type of antihypertensive medication prescribed to black and white Americans. *Hypertension* 2002;39:179-183.
76. Lopes HF, Stojiljkovic MP, Zhang D, Goodfriend TL, Egan BM: Moderate sodium restriction enhances the pressor response to hyperlipidemia in obese hypertensive patients. *J Clin Hypertens* 2002;4:173-180.
77. Egan BM, Lackland DT, Basile JN: American Society of Hypertension Regional Chapters: Leveraging the impact of the clinical hypertension specialist in the local community. *Am J Hypertens* 2002;15:372-379.
78. Stojiljkovic MP, Lopes HL, Zhang D, Morrow JM, Goodfriend TL, Egan BM: Increasing fatty acids increases F2-isoprostanes in humans. Implications for the cardiovascular risk factor cluster. *J Hypertension* 2002;20:1-7.
79. Gadegbeku CA, Dhandayuthapani A, Sadler JE, Egan BM: Raising lipids acutely reduces baroreflex sensitivity. *Am J Hypertension* 2002;15:479-485.
80. Bakris G, Calhoun D, Egan B, Hellmann C, Kingma I: Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertension* 2002;20:2257-2267.
81. Gadegbeku CA, Dhandayuthapani A, Shrayyef MZ, Egan BM: Hemodynamic effects of nicotinic acid infusion in normotensive and hypertensive subjects. *Am J Hypertension* 2003;16:67-71.
82. Lopes HF, Martin KL, Nashar K, Morrow JD, Goodfriend TL, Egan BM: Effects of the DASH Diet on blood pressure, antioxidant capacity and acute lipid-induced oxidative stress. *Hypertension* 2003;41:422-430.
83. Egan BM, Lackland DT, Cutler NE: Awareness, knowledge and attitudes of older Americans about high blood pressure: Implications for healthcare policy, education and research. *Arch Int Med* 2003;163:681-687.
84. Lopes HF, Morrow JD, Stojiljkovic MP, Goodfriend TL, Egan BM: Acute hyperlipidemia increases oxidative stress more in African Americans than in Caucasian Americans. *Am J Hypertens* 2003;16:331-336.
85. Giese M, Lackland D, Basile J, Egan B: 2003 Update on the hypertension initiative of South Carolina. *J South Carolina Med Assoc* 2003; 99:157-161.
86. Hendrix K, Lackland DT, Egan BM: Cardiovascular risk factor control and treatment patterns in primary care. *Managed Care Interface* 2003;16:21-26.
87. Basile JN, Lackland DT, Basile JM, Riehle JE, Egan BM: A statewide primary care approach to cardiovascular risk factor control in high-risk diabetic and non-diabetic patients with hypertension. *J Clin Hypertension* 2004;1:18-25.
88. King DE, Egan BM, Geesey ME: Relation of dietary fat, fiber to elevation of C-reactive protein. *Am J Cardiol* 2004;92:1335-1339.

89. Lackland DT, Lin Y, Tilley BC, Egan BM: Assessment of racial differences in clinical practices for hypertension at primary care sites for medically underserved patients. *J Clin Hypertens* 2004;6:26–33.
90. Nashar K, Nguyen JP, Jesri A, Egan BM: Angiotensin receptor blockade improves arterial distensibility and reduces exercise-induced pressor responses in obese hypertensive patients with the metabolic syndrome. *Am J Hypertens* 2004;17:477–482.
91. Julius S, Nesbitt S, Egan B, Kaciroti N, Schork MA, Grozinski M, Michelson E. Trial of Preventing Hypertension (TROPHY): Design and 2-year progress report. *Hypertension* 2004;44:146–151.
92. Gadegbeku CA, Shrayyef MZ, Egan BM. Lipids enhance α_1 -adrenoceptor pressor and baroreflex sensitivity in patients with chronic kidney disease. *Am J Kid Dis* 2004;44:446–454.
93. Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithiptikom K: An epoxy-ketoderivative of linoleic acid stimulates aldosterone secretion by rat adrenal cells, and its levels in human blood correlate with aldosterone. *Hypertension* 2004;43:358–363.
94. Bestermann WH, Lackland DT, Riehle JE, Egan BM: A systematic approach to managing hypertension and the metabolic syndrome in primary care. *S Med J* 2004;97:932–938.
95. King DE, Egan BM, Mainous AG, Geesey ME: Elevated C-reactive protein in people with prehypertension. *J Clin Hypertension* 2004;6:562–568.
96. Mainous AG, Liszka HA, Geese ME, King DE, Egan BM: Prehypertension and mortality in a nationally representative cohort. *Am J Cardiol* 2004;94:1496–1500.
97. Egan BM, Papademetriou V, Wofford M, Calhoun D, Fernandez J, Riehle JE, Nesbitt S, Julius S: Metabolic syndrome and insulin resistance: Contrasting views in patients with high normal blood pressure. *Am J Hypertension* 2005;18:3–12.
98. Sheats N, Lin Y, Zhao W, Cheek DE, Lackland DT, Egan BM: Prevalence, treatment, and control of hypertension among African Americans and Caucasians at primary care sites for medically underserved patients. *Ethnic Dis* 2005;15:25–32.
99. Hendrix KH, Riehle JE, Egan BM: Ethnic, gender, and age-related differences in treatment and control of dyslipidemia in hypertensive patients. *Ethnic Dis* 2005;15:11–16.
100. Rehman SU, Hutchison FN, Hendrix K, Okonofua EC, Egan BM: Comparison of ethnic differences in blood pressure control at VA and non-VA sites. *Arch Int Med* 2005;165:1041–1047.
101. Nesbitt SN, Julius S, Leonard D, Egan BM, Grozinski M, for the TROPHY Study Investigators: Is low-risk hypertension fact or fiction? Cardiovascular risk profile in the TROPHY Study. *Am J Hypertens* 2005;18(7):979–984.
102. Miller PM, Anton RF, Egan BM, Basile J, Nguyen SA: Excessive alcohol consumption and hypertension: Clinical implications of current research. *J Clin Hypertens* 2005; 7(6):346–351.
103. Okonofua EC, Cutler NE, Lackland DT, Egan BM: Ethnic differences in older Americans: Awareness, knowledge and beliefs about hypertension. *Am J Hypertens* 2005;18:972–979.
104. Hendrix KH, Mayhan S, Egan BM: Gender- and age-related differences in treatment and control of cardiovascular risk factors among high-risk patients with angina. *J Clin Hypertens* 2005;7:386–394.
105. Riehle JE, Lackland DT, Okonofua EC, Hendrix KH, Egan BM: Ethnic differences in treatment and control of hypertension in patients with diabetes. *J Clin Hypertension* 2005;7:445–454.
106. Hendrix KH, Mayhan S, Lackland DT, Egan BM: Demographic differences in the prevalence and treatment of chest pain syndromes and in the control of cardiovascular risk factors: A comparison of hypertensive patients with and without chest pain. *Am J Hypertension* 2005;18:1026–1032.
107. King DE, Mainous AG, Egan BM, Woolson RF, Geesey ME: Fiber and C-reactive protein in diabetes, hypertension, and obesity. *Diabetes Care* 2005; 28:1487–1489.
108. Liszka HA, Mainous AG, King DE, Everett CJ, Egan BM. Prehypertension and cardiovascular morbidity. *Ann Fam Med* 2005;3:294–299.
109. Coffee RE, Nicholas JS, Egan BM, Rumboldt Z, D’Agostino S, Patel SJ: Arterial compression of the retro-olivary sulcus of the medulla in essential hypertension: A multivariate analysis. *J Hypertension* 2005;11:2027–2031.
110. Jesri A, Okonofua EC, Egan BM: Platelet and white blood cell counts are elevated in patients with the metabolic syndrome. *J Clin Hypertension* 2005;7:705–711.
111. Okonofua EC, Simpson K, Jesri A, Rehman S, Durkalski V, Egan BM: Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. *Hypertens* 2006;47:1–7.

112. Miller, PM, Spies C, Neumann T, Javors MA, Hoyumpa AM, Roache J, Webb A, Kashi M, Sharkey FE, Anton RF, Egan BM, Basile J, Nguyen S, Fleming MF, and Dillie KS: Alcohol biomarker screening in medical and surgical settings. *Alcoholism: Clin Exper Res* 2006;30:185–193.
113. Julius S, Nesbitt S, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH, Jr., Leonard D, Messerli FH, Oparil S, Schork MA for TROPHY Investigators: A Therapeutic Intervention to Change the Natural History of Prehypertension: The TROPHY Study Main Results. *N Engl J Med* 2006;354:1685–1697.
114. King DE, Egan BM, Mainous AG, Geesey ME: The effect of extended-release metoprolol succinate on C-reactive protein levels in people with hypertension. *J Clin Hypertension* 2006;8:257–260.
115. King DE, Mainous AG, Geesey ME, Egan BM, Rehman S: Magnesium supplement intake and C-reactive protein levels in adults. *Nutr Res* 2006;26:193–196.
116. Egan BM, Lackland DT, Igho-Pemu P, Hendrix KH, Basile J, Rehman SU, Okonofua EC, Quarshie A, Oduwole A, Onwuanyi A, Reed J, Obialo C, Ofili EO: Cardiovascular risk factor control in communities—Update from the ASH Carolinas-Georgia Chapter, the Hypertension Initiative, and the Community Physicians’ Network. *J Clin Hypertens* 2006;12:879–886.
117. Gadegbeku CA, Shrayyef Z, Taylor TP, Egan BM: Mechanism of lipid enhancement of α_1 -adrenoceptor pressor sensitivity in hypertension. *J Hypertension* 2006;24:1383–1389.
118. Fan ZJ, Lackland DT, Lipsitz SR, Nicholas BM, Egan BM, Garvey WT, Hutchison FN: Geographical patterns of end-stage renal disease incidence and risk factors in rural and urban areas of South Carolina. *Health & Place* 2007;13:179–187.
119. King DE, Egan BM, Woolson RF, Mainous A, Al-Solaiman Y, Jesri A: The effect of high fiber DASH diet and high fiber-supplemented diet on inflammatory markers. *Arch Int Med* 2007;167:502–506.
120. Abell JE, Egan BM, Wilson PW, Lipsitz S, Woolson RF, Lackland DT: Age and race impact the association between BMI and CVD mortality in women. *Publ Health Rep* 2007;122:507–512.
121. Gilliard TS, Lackland DT, Mountford KE, Egan BM: Concordance between self-reported heights and weights and current and ideal body images in young adult African American men and women. *Ethnic Dis* 2007;17:617–623.
122. King DE, Mainous AG, Egan BM, Player M, Geesey ME: Use of statins and blood pressure. *Am J Hypertens* 2007;20:937–941.
123. Gadegbeku CA, Dhandayuthapani A, Taylor TP, Shrayyef Z, Gerich J, Garvey WT, Egan BM: Insulin’s actions on plasma fatty acids are normal in patients with Stage 2–3 chronic kidney disease. *J Am Soc Hyperten* 2007;1:414–422.
124. Abell JE, Egan BM, Wilson PW, Lipsitz S, Woolson RF, Lackland DT: Differences in cardiovascular disease mortality associated with body mass between Black and White persons. *Am J Publ Health* 2008;98:63–66.
125. Julius S, Kaciroti N, Egan BM, Nesbitt S, Michelson EL: TROPHY Study: Outcomes based on the JNC 7 definition of hypertension. *JASH* 2008;2:39–43.
126. King DE, Mainous AG, Egan BM, Woolson RF, Geesey ME: The effect of psyllium fiber supplementation on C-reactive protein: The trial to reduce inflammatory markers (TRIM). *Ann Fam Med* 2008;6:100–106.
127. Williams SA, Michelson EL, Cain VA, Yan M, Nesbitt SD, Egan BM, Julius S: An evaluation of the effects of candesartan on health-related quality of life in patients with high normal blood pressure (prehypertension) in the Trial of Preventing Hypertension (TROPHY). *J Clin Hypertens* 2008;10:436–442.
128. Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Keefe DL: Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: A 6-month, randomized, double-blind, trial. *J Hypertension* 2008;26:589–599.
129. Lackland DT, Egan BM, Mountford WK, Boan AD, Evans DA, Gilbert GE, McGee DL: Thirty-year survival for black and white individuals in the Evans County Heart Study and the Hypertension Detection and Follow-up Program. *J Am Soc Hypertens* 2008;2:448–454.
130. Axon RN, Bradford WD, Egan BM: The role of individual time preferences in health behaviors among hypertensive adults. A pilot study. *J Am Soc Hypertens* 2009;3:35–41.

131. Al-Solaiman Y, Jessri A, Zhao Y, Morrow JD, Egan BM: Low sodium DASH reduces oxidative stress and improves vascular function in salt-sensitive humans. *J Hum Hypertens* 2009;(accepted for publication).
132. Egan BM, Basile JN, Rehman SU, Strange P, Grob C, Riehle J, Walters C, Lackland DT, Sealey JE, Laragh JH: Renin-guided algorithm matches clinical hypertension specialist care in uncontrolled hypertension: A randomized-controlled clinical trial. *Am J Hypertens* 2008 (accepted for publication).
133. Al-Solaiman Y, Jesri A, Mountford WK, Lackland DT, Zhao Y, Egan BM: DASH lowers blood pressure in obese hypertensives beyond potassium, magnesium and fiber. *J Hum Hypertens* (in review).
134. Howard VJ, Woolson RF, Egan BM, Nicholas JS, Adams RJ, Howard G, Lackland DT: Prevalence of hypertension by duration and exposure to the stroke belt. *Hypertension* (in revision).
135. Allaire BT, Trogdon JG, Egan BM, Lackland DT, Masters D, Orenstein D: Measuring the impact of a continuing medical education program on patient outcomes. In preparation.
136. Trogdon JG, Allaire BT, Egan BM, Lackland DT, Masters D, Orenstein D: Training providers in hypertension guidelines: Cost effectiveness evaluation of a continuing medical education program in South Carolina. In preparation.
137. Mountford WK, Hunt KJ, Egan BM, Woolson RF, Lipsitz SR, Slate EH, Colwell JA, Lackland DT: Similar association between systolic blood pressure level and cardiovascular disease mortality for blacks and whites. In preparation.
138. Egan BM, Sheats NC, Lin Y, Tilley BC: Ethnic differences in the prevalence, treatment, and control of type 2 diabetes and concomitant hypertension. In preparation.
139. Hendrix KH, Tang S, Thakker K, Lackland D, Egan B: Adding dihydropyridine calcium channel blockers lower blood pressure in diabetic hypertensives irrespective of baseline treatment and demographics. *JASH* (in revision).
140. Lopes HF, Klein R, Garvey WT, Goodfriend TL, Egan BM: Plasma leptin, ASP/C3adesARG, and adiponectin in lean normotensive and metabolic syndrome subjects at baseline and during acute hyperlipidemia. *JASH* (in preparation).
141. Hendrix KH, Tang S, Thakker K, Lackland D, Egan B: Diagnosis and treatment of hyperlipidemia in diabetics with and without hypertension. In preparation.

Books, Monographs, Reviews, Commentaries & Letters:

1. Egan B, Julius S: Borderline hypertension. Symposium on Hypertension in Office Practice. In: Primary Care, (Black HR, Editor), 10:99-113, 1983.
2. Julius S, Weder AB, Egan BM: Pathophysiology of early hypertension: Implications for epidemiologic research. In: Mild Hypertension: Recent Advances, (Gross F, Strasser T, Editors) Raven Press, New York, 1983, pp. 219-236.
3. Egan B, Julius S: Risk factors in youth for subsequent hypertension. *Prac Cardiol* 1983;9:120-133.
4. Egan B: How to treat the mild hypertensive without drugs. *Mod Med* April 1984:78-83.
5. Egan B: Nonpharmacologic treatment of hypertension. *Prac Cardiol* 1984;10:50-64.
6. Julius S, Fitzpatrick MA, Egan B, Schneider R: Neural mechanisms in clinical hypertension. In: Hypertension and the Brain, (Guthrie, Jr GP, Kotchen TA, Editors) Futura Publications, New York, 1984, pp. 305-318.
7. Egan B: Nutritional and lifestyle approaches to the prevention and management of hypertension. Comprehensive Ther 1985;11:15-20.
8. Julius S, Schneider R, Egan B: Suppressed anger in hypertension: Facts and problems. In: Anger and Hostility in Behavioral and Cardiovascular Disorders, (Chesney MA, Rosenman R, Editors) Hemisphere Publishing Corp., Washington, D.C., 1985, pp. 127-137.
9. Julius S, Egan B, Hinderliter A: Assessment of autonomic function in essential hypertension. In: Neuroregulation of Autonomic, Endocrine, and Immune Systems, (Frederickson RCA, Henrie HC, Hingtgen JN, Aprison MH, Editors) Martinus-Nijhof, Boston, 1986, pp. 183-98.

10. Julius S, Egan B: Hemodynamics of hypertension. In: Handbook of Hypertension, Vol. 7: Pathophysiology of Hypertension - Cardiovascular Aspects, (Zanchetti A, Tarazi RC, Editors) Elsevier, Amsterdam, 1986, pp. 153-178.
11. Egan BM, Julius S: Cardiac reflexes and blood pressure elevation. In: Hypertension and the Heart, (Messerli FH, Ed.) Cahners Publishing Co., Yorke Medical Books, 1987, pp. 11-19.
12. Egan BM: Hypertension control: Usefulness of self-monitoring. *Mod Med* 1987;55:54-8.
13. Egan BM: Changed sympathetic tone and responsiveness in the course of human essential hypertension. In: Handbook of Hypertension, Vol 9: Behavioral Factors in Hypertension, (Julius S, Bassett DR, Editors) Elsevier, Amsterdam, 1987, pp. 216-225.
14. Egan BM: Adrenergic receptor mechanisms in hypertension. *Hypertension Highlights, Associates in Medical Marketing* 1988;9:1-8.
15. Johnson EH, Egan BM: Ambulatory and home blood pressure monitoring in clinical medicine. *Cardio* pp. 95-114, September 1988.
16. Egan BM, Julius S: The hemodynamics of borderline hypertension. In: The Heart and Hypertension: A tribute to Robert Tarazi (1925-1986). (Safar ME, Fouad Tarazi FM, Editors) Kluwer Academic Publishers, pp. 47-66, 1989.
17. Egan BM: Correspondence: Adaptive changes in cerebral blood vessels during chronic hypertension. *J Hypertension* 1992;10:399-400.
18. Egan BM: Vascular alpha-adrenergic reactivity and tone in mild hypertension. In: Personality, Elevated Blood Pressure and Essential Hypertension, (Johnson EH, Gentry WD, Julius S, Editors) Hemisphere Publishing Corporation, New York, pp. 231-256, 1992.
19. Egan BM: Insulin resistance and hypertension. In: *Chances Are: Clinical probabilities in hypertension*, (Di Pette DJ, Editor) Healthscan Publ., Cedar Grove, NJ, vol 3 (2):3-6, 1992.
20. Egan BM: Letter: Hypertension, diuretics and coronary heart disease: A case of apples and oranges, reciprocal prejudice and a partially clad emperor? *Am J Hypertension* 1992;5:665-666.
21. Egan BM, Stepniakowski K: Peripheral vasomotor control in essential hypertension. In: Primer on Hypertension. Izzo JL and Black HR, ed., Am. Heart Assoc., pp 68-70, 1993.
22. Egan BM, Stepniakowski K, Sagar K: Abnormal signal-averaged ECGs in elderly hypertensives with low diastolic blood pressure. *Cardiology Board Review* 1994;11:30-40.
23. Egan BM, Stepniakowski K: Vascular alpha-adrenergic tone in obesity and salt sensitive hypertension. In: Hypertension: Pathophysiology, Diagnosis, and Management. JH Laragh and BM Brenner, Editors, Raven Press, New York, 2nd ed., vol. 2, pp 2693-2702, 1995.
24. Egan BM, Stepniakowski KT: Evidence linking fatty acids, the risk factor cluster, and vascular pathophysiology: Implications for the diabetic hypertensive patient. In: Diabetes and vascular disease. JR Sowers, editor, Humana Press, Tocowa, NJ, 1996; chap 12, pp. 157-172.
25. Basile J, Egan B: (invited book review) Individualized therapy of hypertension, NM Kaplan & CVS Ram, Editors, Marcel Dekker, Inc., 1996. *Circulation* 1996;23:9-10.
26. Egan BM, Stepniakowski KT: Adverse metabolic effects of short-term very low salt diets in subjects with risk factor clustering. *Am J Clin Nutr* 1997;65(suppl):671S-677S.
27. Hall WD, Ferrario CM, Moore MA, Hall JE, Flack JM, Cooper W, Simmons JD, Egan BM, Lackland DT, Perry M, Roccella EJ: Hypertension-related morbidity and mortality in the southeastern United States. *Am J Med Sci* 1997;313:195-209.
28. Goodfriend TL, Egan BM: Nonesterified fatty acids in the pathogenesis of hypertension: Theory and evidence. *Prostaglandin Leukotrien Essen Fatty Acids* 1997;57:57-63.
29. Egan BM: Fatty acids and neurovascular regulation: A possible link between insulin resistance and hypertension. *Current Concepts in Hypertension* 1997;2:5.
30. Egan BM, Lackland DT: Strategies of prevention and the importance of public health and community programs. *Ethnicity & Disease* 1998;8:143-154.
31. Goodfriend TL, Egan BM, Kelley DE: Aldosterone in obesity. *Endocrine Research* 1998;24:789-796.
32. Egan BM: Cardiovascular effects of fatty acids. Hypertension Primer, American Heart Association, Eds. JL Izzo and HR Black, 2nd ed., 1999, pp. 35.
33. Egan BM: Obesity hypertension, angiotensin and vascular remodeling. *VALUE Trial Newsletter*. February, 1999, pp.4,5.

34. Egan BM, Lu G, Greene EL: Vascular effects of non-esterified fatty acids: Implications for the cardiovascular risk factor cluster. *Prostaglandin Leukotrien Essen Fatty Acids* 1999;60:411-420.
35. Goodfriend TL, Egan BM, Kelley DE: Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. *Prostaglandin Leukotrien Essen Fatty Acids* 1999;60:401-405.
36. Egan BM: Cardiovascular risk and hypertension. *Current Hypertension Reports* 1999;1(3):199-201.
37. Jones D, Basile J, Cushman W, Egan B, Ferrario C, Hill M, Lackland D, et al: Managing hypertension in the Southeastern United States: Applying the JNC VI guidelines. *Am J Med Sci* 1999;318:357-364.
38. Lackland DT, Egan BM: The dominant role of systolic hypertension as a vascular risk factor: Evidence from the Southeast. *Am J Med Sci* 1999;318:365-368.
39. Egan BM, Lackland DT: Biochemical and metabolic effects of very low salt diets. *Am J Med Sci* 2000;320:233-239.
40. Lackland DT, Egan BM, Bendall HE, Osmond C: Low birth weight and the emerging burden of renal disease in the United States. In: Fetal origins of cardiovascular and lung disease. Editor, DJP Barker. Marcel Dekker, Inc., 2000.
41. Giese M, Lackland DT, Egan BM: The Hypertension Initiative of South Carolina: Promoting cardiovascular health through better blood pressure control. *J South Carolina Med Assoc* 2001;97:57-62.
42. Lackland DT, Egan BM, Fan J: Low birth weight contributes to the excess prevalence of hypertension and end-stage renal disease in African Americans. *J Clin Hypertension* 2001;3:29-31.
43. Egan BM, Greene EL, Goodfriend TL: The metabolic syndrome and the role of nonesterified fatty acids in blood pressure control and complications. *Current Hypertension Reports* 2001;3:107-116.
44. Egan BM, Greene EL, Goodfriend TL: Insulin resistance and cardiovascular disease. *Am J Hypertension* 2001;14 [part 2]:116S-125S.
45. Egan BM: Editorial commentary: The role of vascular biology, nutrition, and nutraceuticals in the prevention and treatment of hypertension. *J Am Nutraceut Assoc (JANA)* 2002;April (suppl 1):1-2.
46. Egan BM: Editorial: Ethnicity and unprovoked hypokalemia in the ARIC study. *Am J Hypertension* 2002;15:660-1.
47. Egan BM: Editorial Commentary: Non-narcotic analgesic use and the risk of hypertension in U.S. women. *Hypertension* 2002;40:601-603.
48. Egan BM: Insulin resistance and the sympathetic nervous system. *Curr Hypertens Rep* 2003;5:247-254.
49. Egan BM: Editorial commentary: Reproducibility of individual blood pressure responses to changes in dietary salt intake: Compelling evidence for universal sodium restriction? *Hypertension* 2003;42:457-58.
50. Egan BM, Basile JN, Lackland DT (editors): Hot Topics in Hypertension: 2003, Hanley & Belfus, Philadelphia, PA.
51. Egan BM, Basile JN: Controlling blood pressure in 50% of all hypertensive patients: an achievable goal in the Healthy People 2010 Report? *J Invest Med* 2003;51:373-385.
52. Egan BM: β -blockers for cardioprotection: A forgotten message. *Postgrad Med—A special report* 2004;3.
53. Cohen JD, Egan BM: The role of sympathetic activation in cardiovascular disease. *Postgrad Med—A special report* 2004;4-10.
54. Egan BM, Chilton RJ: Other important applications for β -blockers in high-risk patients. *Postgrad Med—A special report* 2004;35-48.
55. Egan BM: Letter – Universal Salt Reduction. *Hypertension* 2004;43:e12-e13 (electronic).
56. Egan BM, Basile JN: Controlling blood pressure in 50% of all hypertensive patients—an achievable goal in the Health People 2010 Report? *Business Briefing: North American Pharmacotherapy* 2004;February:125-129.
57. Egan BM (guest editor and reviewer): Presentations in Focus: Reports and Expert Commentary. From hypertension to heart failure: Strategies for prevention and opportunities for treatment. Rogers Medical Intelligence Solutions, 2004.
58. Egan BM, Julius S: Role of sympathetic overactivity in the pathophysiology of the metabolic syndrome. *Dialog Cardiovasc Med* 2004;9:143-157.
59. Egan BM: Editorial commentary. Hypertension in the 21st century: The tide is rising; our daze must end. *Hypertension* 2004;44:389.

60. Egan B, Gleim G, Panish J: Primary care review of LIFE and RENAAL outcomes among diabetic patients. *Curr Med Res Opin* 2004;20:1909–1917.
61. Houston MC, Basile J, Bestermann WH, Egan B, Lackland D, Hawkins RG, Moore MA, Rogers P, Wise D, Ferrario CM: Addressing the global cardiovascular risk of hypertension, dyslipidemia, and insulin resistance in the Southeastern United States. *Am J Med Sci* 2005;329:276–291.
62. Bestermann W, Houston MC, Basile J, Egan B, Ferrario CM, Lackland D, Hawkins RG, Reed J, Rogers P, Wise D, Moore MA: Part II: Treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus and the metabolic syndrome. *Am J Med Sci* 2005;329:292–305.
63. Egan BM, Okonofua EC: The clinician's role in improving therapeutic adherence and blood pressure in older hypertensive patients. In: Cardiovascular Health and Vascular Diseases. Prisant M, editor., Humana Press Inc., Totowa, New Jersey, 2005;ch 24:491–517.
64. Egan BM, Basile JN, Chilton RJ, Cohen JD: Cardioprotection: The role of β -blocker therapy. *J Clin Hypertension* 2005;7:409–416.
65. Houston MC, Egan BM: The metabolic syndrome: Pathophysiology, diagnosis, clinical aspects, prevention and nonpharmacologic treatment: Emphasis on lifestyle modifications, nutrition, nutritional supplements, vitamins, mineral, antioxidants, weight management and exercise. *J Am Nutra Assoc* 2005;8:3–83.
66. Rehman SU, Hutchison FN, Okonofua EC, Hendrix KH, Egan BM: Ethnic differences in blood pressure control in men. *Cardiol Rev* 2006;23:27–31.
67. Egan BM: Challenges and risks in attaining the systolic blood pressure goal of <130 mm Hg in all diabetic patients. *J Clin Hypertension* 2006;8:50–52.
68. Egan BM: Sleep and hypertension: Burning the candle at both ends really is hazardous to your health. *Hypertension* 2006;47:816–817.
69. Egan BM: Is microalbuminuria related to the metabolic syndrome? In: Microalbuminuria: The importance of treatment and prevention. L Ruilope, Ed., Sankyo Co., Ltd., publ., 2006;pp.36–44.
70. Egan BM: Should Metabolic Syndrome Patients with Pre-Hypertension Receive Antihypertensive Therapy? In: Therapeutic Strategies in Hypertension, GL Bakris, Ed., Clin Publ, Oxford, UK, 2006; ch 2, pp. 9–25.
71. Lopes HF, Egan BM: Autonomic dysregulation and the metabolic syndrome: Pathologic partners in an emerging global pandemic. Review. *Arq Bras Cardiol* 2006;87:538–547.
72. Messerli FH, Bangalore S, Egan BM, Julius S: Does life-long reduction in low-density lipoprotein cholesterol reduce the risk of new-onset hypertension? *Am J Cardiol* 2006;98:1122.
73. Julius S, Schork A, Egan BM: From TROPHY with pride (author reply). *Am J Hypertens* 2007;20:342–343.
74. Lackland DT, Egan BM: Dietary salt restriction and blood pressure in clinical trials. *Curr Hypertens Reports* 2007;9:314–319.
75. Egan BM: Combination therapy with an angiotensin converting enzyme inhibitor and a calcium channel blocker. *J Clin Hypertens* 2007;9:783–789.
76. Egan BM, Nesbitt SD, Julius S: Prehypertension: Should we be treating with pharmacologic therapy? *Ther Adv Cardio Dis* 2008;2:305–314.
77. Egan BM, Julius S: Prehypertension: Risk Stratification and Management Considerations. *Curr Hypertens Rep* 2008;10:359–366.
78. Egan BM: Commentary: Blood pressure associated with sleep-disordered breathing in a population sample of children. *Hypertension* 2008;52:807.
79. Egan BM: Commentary: Fixed-dose combinations and hypertension control in community-based practices: Application of the 'keep it simple' principle. *Hypertension* 2009;53:598–599.

Published Abstracts:

1. Egan B, Colfer H, Buda A, Julius S: Evidence that the sympathetic nervous system contributes to cardiovascular hypertrophy in patients with borderline hypertension. *Clin Res* 1984;32:330A.
2. Egan B, Fitzpatrick MA, Julius S: Renin release during pharmacologic alteration of baroreceptor load. *Clin Res* 1984;32:790A.

3. Egan BM, Hinderliter A, Julius S: Vascular alpha-adrenergic reactivity in normotensive humans. *Clin Res* 1985;33:360A.
4. Shenker Y, Bates, ER, Egan B, Grekin RJ: Infusion of vasopressors increases IR-ANH levels in normal men: First World Congress of Biologically Active Atrial Peptides, New York, NY, May 1986, p. 87A.
5. Egan B, Hinderliter A, Panis R, Julius S: Vascular structure is a determinant of resistance response. *Clin Res* 1986;34:478A.
6. Egan B, Campbell R, Conlon L, Zweifler A: Ketanserin inhibits serotonin (5HT) and 5HT potentiated platelet aggregation. *Clin Res* 1986;34:907A.
7. Egan BM, Panis R, Hinderliter A: The vascular abnormality in mild hypertension. *Clin Res* 1987;35:441A.
8. Weder AB, Egan BM: RBC water, Na⁺-K⁺ cotransport and vascular waterlogging in human hypertension. *Clin Res* 1987;35:451A.
9. Egan B, Bassett D: Does insulin participate differentially in the effects of overweight on cardiovascular risk in men versus women < 45 years old? *Clin Res* 1987;35:847A.
10. Egan B, Weder A: Determinants of regional vascular alpha-adrenergic tone. *Clin Res* 1987;35:843A.
11. Egan B, Schork N: Increased vascular alpha-tone contributes to the inappropriately normal peripheral resistance in overweight men. *Clin Res* 1987;35:830A.
12. Egan BM, Schork NA, Julius S: Mechanism of inappropriately normal peripheral resistance in overweight men. *Circulation* 1987;76(Suppl 2):209.
13. Egan B, Schmouder R: Cardiac power in borderline hypertension and obesity. *Am J Hypertension* 1988;1:3 (part 2):6A.
14. Egan BM, Juni J, Buda A, Zweifler A: Does weight contribute to cardiac abnormalities in borderline hypertension? *Am J Hypertension* 1988;1:3 (part 2):8A.
15. Egan B, Petrin J, Julius S: Systemic arterial compliance in borderline hypertension. *Am J Hypertension* 1988;1:3 (part 2):8A.
16. Egan B, Petrin J, Mejia A, Weder AB: Differential changes in blood pressure, regional vascular responses, and plasma renin activity to alterations in dietary salt. *Am J Hypertension* 1988;1:3 (part 2):9A.
17. Egan B, Zweifler AJ: Does ketanserin reduce alpha-adrenergic tone by lowering sympathetic drive? *Am J Hypertension* 1988;1:3 (part 2):25A.
18. Egan BM, Bassett DR: Effects of gender and weight on blood pressure and insulin values in subjects < 45 years. *Am J Hypertension* 1988;1:3(part 2):48A.
19. Mejia AD, Egan BM, Zweifler AJ: Is resistant hypertension an artefact of blood pressure measurement? *Clin Res* 1989;37(2):396A.
20. Supiano MA, Stoltz AM, Sekkarie A, Egan B, Neubig RR, Perry TJ, Halter JB: Up-regulation of vascular alpha-adrenergic responsiveness in young and older humans. *Clin Res* 1989;37(2):528A.
21. Egan B, Weder A: Deleterious effects of NaCl restriction. *Circulation* 1989;80 (suppl 2):415.
22. Goodfriend TL, Ball DL, Moore T, Weder A, Egan B, Weinberger M: Salt loads lower plasma insulin and raise fatty acids that inhibit aldosterone. *Hypertension* 1990;16:317.
23. Kenny D, Warltier DC, Hoffmann RG, Egan BM: Fish oil reduces forearm vascular resistance responses to angiotensin. *Clin Res* 1991;39:375A.
24. Egan BM, Hoffmann RG, Gruchow HW, Sasse EA, Kissebah AH, Barboriak JJ: Effects of overweight and age on cardiovascular risk factors in men. *Clin Res* 1991;39:411A.
25. Egan B, Hoffmann R: Effects of NaCl restriction and converting enzyme inhibition on insulin and blood pressure in hypertensive men with upper body obesity. *Clin Res* 1991;39:432A.
26. Egan BM, Sekulic D, Hoffmann RG: Vasoconstrictor vs volume mechanisms in the blood pressure response to converting enzyme inhibition during a low NaCl diet. *Clin Res* 1991;39:432A.
27. Egan BM, Hoffmann RG: Obesity, subcutaneous body fat distribution, and blood pressure in black and white women. *Clin Res* 1991;39:701A.
28. Kenny D, Warltier DC, Goodfriend TL, Egan BM: Fish oil attenuates the vasoconstrictor response to angiotensin and not alpha-adrenergic stimulation in man. *JACC* 1992;19:212A.
29. Neahring JM, Myers T, Hoffmann RG, Egan BM: Insulin does not antagonize forearm vascular alpha-adrenergic reactivity in man. *Am J Hypertension* 1992;5:17A.

30. Egan BM, Stepniakowski K, Hoffmann RG: Effects of severe, short-term dietary NaCl restriction on the hemodynamic response to glucose and insulin in patients with mild hypertension. *Am J Hypert* 1992;5:75A.
31. Egan BM, Hoffmann RG, Kissebah AH, Barboriak JJ, Sasse EA, Gruchow HW: Differential effects of overweight on cardiovascular risk factors in younger vs. older men and women. *Am J Hypert* 1992;5:98A.
32. Neahring M, Hoffmann RG, Egan BM. Insulin's regional vascular actions are not altered in men with mild hypertension. *Clin Res* 1992;40:244A.
33. Stepniakowski K, Myers T, Egan B. Short-term dietary NaCl restriction raises 24-hr. and laboratory BP in patients with mild hypertension. *Clin Res* 1992;40:427A.
34. O'Shaughnessy IO, Nazzaro P, Kissebah AH, Egan BM. Insulin sensitivity is similarly reduced in abdominally obese hypertensives and normotensives. *Circulation* 1992;86:I-541.
35. Shin HH, Sagar KB, Wetherbee JN, Egan BM. Aggressive blood pressure control might contribute to the J-phenomenon in hypertensive patients by increasing risk for arrhythmias. *Circulation* 1992;86:I-585.
36. Fleissner MJ, Neahring MJ, Ebert TJ, Egan BM. Pharmacologic improvement of baroreflex sensitivity in elderly hypertensives is not explained only by blood pressure reduction. *Circulation* 1992;86:I-778.
37. Shin HH, Sagar KB, Wetherbee JN, Egan BM. Increased prevalence of abnormal signal-averaged ECGs hypertensive white men may contribute to adverse outcome with diuretic therapy. *Clin Res* 1992;40:699A.
38. O'Shaughnessy IO, Nazzaro P, Egan BM, Kissebah AH. Does hypertension intensify insulin resistance in upper body obese adults? *Clin Res* 1992;40:734A.
39. Neahring JM, Stepniakowski K, Egan BM. Insulin directly vasodilates the human forearm vasculature. *Clin Res* 1992;40:740A.
40. Neahring JM, Stepniakowski K, Egan BM. The forearm vascular wall response to insulin is normal in obese men with mild hypertension and insulin resistance. *Am J Hypertension* 1993;6:1A.
41. Stepniakowski K, Neahring JM, Nazzaro P, Egan BM. Volume expansion on high vs low NaCl diets and insulin metabolism are similar in obese salt-sensitive and resistant subjects. *Am J Hypertens* 1993;6:1A.
42. Neahring JM, Stepniakowski K, Egan BM. Insulin non-specifically augments forearm vascular reactivity to norepinephrine in normal volunteers. *Am J Hypertension* 1993;6:83A.
43. Lackland D, Egan B, Cheek D, Dunbar J. Racial differences in the use of office-based medical services for blood pressure assessment. *Am J Hypertension* 1993;6:88A.
44. Egan BM, Stepniakowski K, Nazzaro P: Volume expansion and insulin are similar in obese salt-sensitive and salt-resistant hypertensives. *Hypertension* 1993;21:529.
45. Stepniakowski K, Nazzaro P, Egan BM: Hypertension in abdominally obese adults <45 years old is not salt sensitive. *Hypertension* 1993;22:433A.
46. Neahring JM, Stepniakowski K, Egan BM: Forearm vascular alpha-receptor sensitivity is normal and not altered by insulin in obese men with mild hypertension. *Hypertension* 1993;22:451A.
47. Nazzaro P, Stepniakowski K, O'Shaughnessy IM, Kissebah AH, Egan BM. Hyperinsulinemia does not alter the diurnal BP in obese young men. *Circulation* 1993;88:I-359.
48. O'Shaughnessy IM, Myers TJ, Nazzaro P, Kissebah AH, Egan BM: Glucose metabolism in abdominally obese hypertensive subjects. *Obesity Research* 1993;1[suppl II]:885.
49. Egan BM, Stepniakowski K: Compensatory hyperinsulinemia and the forearm vasodilator response to glucose in obese hypertensives. *Clin Res* 1994;42:119A.
50. Stepniakowski K, Egan BM, Goodfriend TL: A relationship between plasma aldosterone and HDL-cholesterol in humans with varying degrees of cardiovascular risk. *Clin Res* 1994;42:338A.
51. Lackland DT, Egan BM, Keil JE, Gazes PC, Hames CG, Tyroler HA: Greater mortality risk for black hypertensives compared to whites males and females. *Am J Hypertension* 1994;7:32A.
52. Stepniakowski K, Egan BM: Obesity and hypertension have additive effects to limit venous volume. *Hypertension* 1994;24:401.
53. Stepniakowski K, Goodfriend TL, Egan BM: Non-esterified fatty acids alter vascular tone and reactivity in vivo. *Hypertension* 1994;24:374.
54. Hennes MM, O'Shaughnessy IM, Kelly TM, Egan BM, Kissebah AH: Abnormal free fatty acid metabolism in upper-body obese hypertensive and normotensive subjects. *Clin Res* 1994;42:422A.
55. Lu G, Morinelli TA, Meier KE, Rosenzweig SA, Egan BM: Oleic acid-induced mitogenic signalling in human aortic smooth muscle cells: A role for protein kinase C. *J Invest Med* 1995;43:208A.

56. Hennes MM, O'Shaughnessy IM, Egan BM, Kissebah AH: Angiotensin converting enzyme inhibition and improvement of insulin's antilipolytic action in abdominally-obese hypertensives. *J Invest Med* 1995;43:239A.
57. Stepniakowski K, Phillips BD, Sallee FR, Egan BM: Fatty acids selectively augment vascular α_1 -adrenoceptor responses in vivo. *J Invest Med* 1995;43:320A.
58. Davda RK, Ullian ME, Walsh LG, Goodfriend TL, Egan BM: Oleic acid inhibits nitric oxide synthesis and endothelium-dependent vasodilation. *J Invest Med* 1995;43:375A.
59. Kjeldsen SE, Weder AB, Egan B, Neubig R, Zweifler AJ, Julius S: Effects of physiological epinephrine on platelet function and haematocrit in young men. *Am J Hypertens* 1995;8:124A.
60. Stepniakowski KI, Phillips BD, Egan BM: Fatty acids increase endogenous neurovascular reflex responsiveness. *Hypertension* 1995;26:539.
61. Lu G, Egan BM: Synergistic mitogenic effects of oleic acid and angiotensin II. *Hypertension* 1995;26:553.
62. Egan BM, Hennes MMI, O'Shaughnessy IM, Stepniakowski KT, Kissebah AH: Obesity hypertension and insulin-resistant lipolysis. *Hypertension* 1995;26:540.
63. O'Shaughnessy IM, Hennes MM, Egan BM, Kissebah AH: Organ specific regulation of insulin sensitivity by angiotensin converting enzyme inhibition. *Endocrinology* 1995;Suppl:539.
64. Lackland DT, Egan BM, Hudson MB, Jones PJ: Dramatic effects of nativity on strokebelt mortality in blacks. *Am J Hypertens* 1996;9:18A.
65. Lu G, Egan BM: Angiotensin II synergistically augments the mitogenic response to oleic acid through effects on the AT₁ receptor. *Hypertension* 1996;28(3):3.
66. Stepniakowski KT, Goodfriend TL, Egan BM: Fatty acids enhance systemic alpha₁-adrenoceptor pressor sensitivity. *Hypertension* 1996;28(3):9.
67. Lu G, Egan BM: Cytosolic, Ca⁺⁺-independent PKC activity may contribute to the mitogenic effects of oleic acid in rat aortic smooth muscle cells by inducing tyrosine phosphorylation. *Hypertension* 1996;28(3):20.
68. Stepniakowski KT, Egan BM: Fatty acids enhance endothelium-dependent, nitric oxide independent responses to acetylcholine in vivo. *Hypertension* 1996;28(3):42.
69. Goodfriend TL, Kemnitz JW, Egan BM: Plasma aldosterone levels correlate directly with body fat in monkeys and waist/hip ratio in humans. *Int J Obes* 1996;4[suppl I]:22S.
70. Lackland DT, Corley EH, Egan BM, Bailey WP: Hypertension control and outcomes among Medicaid beneficiaries in the strokebelt. *Am J Hypertension* 1997;10:206A.
71. Haastrup AT, Stepniakowski KT, Goodfriend TL, Egan BM: Raising lipids enhances systemic alpha₁-adrenoceptor pressor sensitivity. *Hypertension* 1998;32:592A.
72. Lu G, Greene EL, Nagai T, Egan BM: Reactive oxygen is critical in oleic acid-mediated mitogenic signaling. *Hypertension* 1998;32:621A.
73. Lackland DT, Egan BM, Hudson MB, Jones PJ. Dramatic effects of nativity on stroke belt mortality in blacks. *Am J Hypertens* 1998;9:18A.
74. Lackland D, Egan B, Durkin M, Gunter N, Williams B: Pharmacologic treatment of hypertension among the South Carolina Medicaid population. *Am J Hypertension* 1999;12:96A.
75. Greene EL, Lu G, Egan BM: The central roles of PKC, ROS, and ERKs in oleic acid-induced vascular smooth muscle cell migration. *Hypertension* 1999;34:339(A).
76. Haastrup AT, Egan BM: Infusion of intralipid and heparin leads to generation of 6-keto-prostaglandin F_{1α} in dorsal hand veins. *Hypertension* 1999;34:369(A).
77. Egan B, Lackland D, Williams B, Gunter N: Cost-avoidance opportunities in hypertensive Medicaid beneficiaries. *Am J Hypertension* 2000;13:17A.
78. Lackland D, Egan BM, Syddal HB, Osmond C, Barker DJP: The association of birthweight and the racial disparity in hypertension among black and white Medicaid beneficiaries. *Am J Hypertension* 2000;13:38A.
79. Zhang D, Haastrup A, Morrow J, Egan B: Intralipid raises plasma 8-iso-PGF_{2α} concentrations in normal volunteers. *J Hypertension* 2000;18[suppl 4]:S128.
80. Greene E, Zhang D, Lu G, Egan B: Low-dose N-acetyl-cysteine enhances the mitogenic response to oleic acid in vascular smooth muscle cells. *J Hypertension* 2000;18[suppl 4]:S130.
81. Gadegbeku CA, Dhandayuthapani A, Sadler ZE, Egan BM: Raising plasma fatty acids reduces baroreflex sensitivity. *Hypertension* 2000;36:725(A).

82. Calhoun DA, Egan BM, Li G, Kingma I: Weight management with orlistat is effective in weight loss and diastolic blood pressure reduction in overweight/obese hypertensives, uncontrolled on medication. *Circulation* 2000 [Suppl II]:II-416.
83. Lackland DT, Egan BM Syddall HE, Barker DJP: Association of birth weight and hypertension among black and white Medicaid beneficiaries in the US Stroke Belt. *Am J Hypertension* 2001;14:192A.
84. Egan BM: The role of angiotensin in the pathogenesis and complications of the risk factor cluster. *Am J Hypertension* 2001;14:262A.
85. Egan BM, Lackland DT: Unfavorable outcomes in hypertensive Medicaid recipients raise opportunities for prevention. *Am J Hypertension* 2002;15:9A.
86. Papademetriou V, Gradman A, Egan B, Nesbitt S, Vidt D, Julius S: Utility of blood pressure during submaximal exercise in the risk stratification of patients with high normal blood pressure. *Am J Hypertension* 2002;15:117A.
87. Lopes HF, Walle T, Nashar K, Egan BM: Total antioxidant capacity, an important factor affecting blood pressure responses to diet? *Am J Hypertension* 2002;15:119A.
88. Lopes HF, Egan B: Intralipid and heparin infusion decreases nitrite/nitrate in obese patients with the risk factor cluster. *Am J Hypertension* 2002;15:120A.
89. Lackland DT, Egan BM: Lack of continuous care is associated with higher rates of stroke in hypertensive Medicaid beneficiaries. *Am J Hypertension* 2002;15:142A.
90. Egan B, Bakris G, Calhoun D, Kingma I: Weight loss with Orlistat reduces cardiovascular risk in obese individuals with treated but insufficiently controlled hypertension. *Am J Hypertension* 2002;15:195A.
91. Nesbitt SD, Egan BM, Julius S: High normal blood pressure and co-morbidity in the TROPHY Study. *Am J Hypertension* 2002;15:208A.
92. Egan B, Wofford M, Calhoun D, Nesbitt S, Cohn J, Julius S: Leptin is associated with insulin resistance and impaired small artery distensibility in subjects with high normal blood pressure. *Am J Hypertension* 2002;15:221A.
93. Egan BM, Basile J, Lackland DT: Risk factor treatment and control in the Stroke Belt. *Am J Hypertens* 2003;16:8A.
94. Nashar K, Nguyen J, Egan BM: Losartan enhances arterial compliance and reduces exercise BP in metabolic syndrome patients. *Am J Hypertens* 2003;16:140A.
95. Bestermann W, Lackland DT, Egan BM: A systematic approach to cardiovascular risk factor control in primary care: A report from the Strokebelt. *Am J Hypertens* 2003;16:206A.
96. Egan BM, Basile J, Cheek DE, Lackland DT: Ethnic differences in risk factor control among diabetic hypertensives. *Am J Hypertens* 2003;16:208A.
97. Lackland DT, Egan BM, Colwell J, Feussner J: The impact of hypertension and diabetes on stroke hospitalization. *Am J Hypertens* 2003;16:211A.
98. Patel SJ, Sribnick E, Nicholas J, Egan B: Vasomotor and sympathetic mapping of the human ventro-lateral medulla. *Am J Hypertens* 2003;16:220A.
99. Basile JN, Lackland DT, Basile JM, Riehle JE, Egan BM: A statewide primary care approach to cardiovascular risk factor control in high-risk diabetic and nondiabetic patients with hypertension. *Journal of Clinical Hypertension* 2004; 6:1:18-25.
100. Egan BM, Basile JN, Lackland DT, Hutchison FN: Treatment and control of hypertension at VA and Non-VA sites in the Southeast. *Am J Hypertens* 2004;17:38A.
101. Egan BM, Zile MR, Basile JN, Hutchison FN: Hypertensive heart failure patients: Pharmacologic treatment patterns by primary care physicians in VA and Non-VA settings. *Am J Hypertens* 2004;17:82A.
102. Harmon AR, Lackland DT, Egan B, Hoel D, Thomas J, Nicholas J, Lipsitz S: Hypertension and aortic calcification in a retired worker cohort. *Am J Hypertens* 2004;17:131A.
103. Egan BM, Papademetriou V, Wofford M, Calhoun D, Fernandes J, Riehle JE, Nesbitt S, Julius S: Metabolic syndrome and insulin resistance in the TROPHY Sub-Study: Contrasting views in high normal blood pressure. *Am J Hypertens* 2004;17:180A.
104. Egan BM, Lackland DT, Mayhan S: Prevalence of chest pain or angina in hypertensive patients and their cardiovascular risk factor treatment and control. *Am J Hypertens* 2004;17:190A.
105. Abell J, lackland D, Egan B: Effects of body mass on blood pressure levels among whites and blacks in the Evans County Heart Study. *Am J Hypertens* 2004;17:192A.

106. Hendrix KH, Riehle J, Egan BM: Ethnicity and age related differences in treatment and control of dyslipidemia in hypertensive patients. *Am J Hypertens* 2004;17:198A.
107. Rehman SU, Egan BM, Hutchison FN: Racial differences in blood pressure control rates in the VA Medical Center. *Am J Hypertens* 2004;17:203A.
108. Egan B, Gleim G, Panish J: Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL. *Current Medical Research and Opinions* 2004; 20:12: 1909-1917.
109. Riehle JE, Lackland DT, Egan BM: Blood pressure control and anti-hypertensive medications in a population of diabetic hypertensives in the Southeastern United States. *Am J Hypertens* 2004;17:204A.
110. Egan BM: Controlling hypertension in special populations. *Am J Hypertens* 2004;17:248A.
111. Hendrix KH, Nida AN, Egan BM: Geographic distribution of ethnic and age related differences in treatment and control of hypertensive dyslipidemic patients in primary care. *Ethnic Dis* 2004;14:S2-47.
112. Okonofua EC, Cutler NE, Lackland DT, Egan BM: Ethnic differences in the knowledge, awareness, and beliefs about hypertension in older Americans. *Ethnic Dis* 2004;14:4 S2-48.
113. Egan BM, Hendrix KH, Okonofua EC, Lackland DT, Ofili E. *Ethnic Dis* 2004;14:S2-54.
114. Abell JE, Lackland DT, Lipsitz S, Egan BM, Wilson PW, Woolson RF: Greater blood pressure disparities among leaner white and black individuals. *Am J Hypertens* 2005;18:99A.
115. Hendrix KH, Egan BM, Lackland DT: Prevalence and treatment of chest pain syndromes, hypertension and high cholesterol in primary care. *Am J Hypertens* 2005;18:187A.
116. Jesri A, Okonofua E, Martin K, Romanowska K, Egan BM: DASH is more effective in lowering blood pressure in metabolic syndrome patients than potassium, magnesium and fiber supplements. *Am J Hypertens* 2005;18(5): 197A.
117. Okonofua E, Simpson K, Jesri A, Rehman S, Egan BM: Clinical inertia in hypertension management: Effects on BP control. *Am J Hypertens* 2005;18:41A.
118. Hendrix K, Tang S, Thakker K, Fox J, Egan B: Adding dihydropyridine calcium channel blocker lowers BP in diabetic hypertensives irrespective of baseline treatment and demographics. *J Clin Hypertens* 2006;8:A82.
119. Hendrix K, Tang S, Thakker K, Fox J, Egan B: Hyperlipidemia diagnosis and treatment in hypertensive diabetic patients. *J Clin Hypertens* 2006;8:A202.
120. Lackland DT, Gilbert G, Carter R, Mountford WK, Woolson R, Egan BM: Long-term survival by hypertension status for white and black men and women. *J Clin Hypertens* 2007;9:A61.
121. Mountford WK, Hunt KJ, Colwell JA, Egan BM, Lackland DT: Prevalence and risk associated with elevated systolic blood pressure levels among blacks and whites. *J Clin Hypertens* 2007;9:A63.
122. Andersen K, Weinberger MH, Egan B, Constance CM, Azora V, Baek IY, Lukashovich V: Aliskiren monotherapy lowers blood pressure more effectively than ramipril monotherapy in patients with stage 2 hypertension: Subgroup analysis of a 6-month, double-blind trial. *J Clin Hypertens* 2008;10:A6.
123. Duprez DA, Xu J, Grandits GA, Nesbitt SD, Egan BM, Julius S, Cohn JN: Small artery but not larger artery elasticity predicts development of hypertension in prehypertensive patients: Results from the TROPHY Study. *J Clin Hypertens* 2008;10:A38.
124. Axon RN, Bradford WD, Egan BM: The relationship between hypertensive patients' health discount rates and selected health behaviors. *J Clin Hypertens* 2008;10:A113.
125. Axon RN, Lackland DT, Egan BM: Inpatient antihypertensive medication prescribing practices at a university teaching hospital. *J Clin Hypertens* 2008;10:A133.